Archives: Premium Distribution

June 15, 2022 12:28:19

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has had its peer-reviewed scientific study published in the “International Journal of Molecular Sciences.” Titled “Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes,” the article reports on the study’s efforts to examine the biological activity of tetrahydrocannabivarin (“THCV”), cannabichromene (“CBC”) and other rare cannabinoids as well as the potential these substances have in addressing various skin conditions. The study used a recognized in vitro model of human keratinocytes to analyze how specific cannabinoids interacted with cannabinoid receptors and other endocannabinoid system components; the results indicate that each cannabinoid had distinct biological activity via the endocannabinoid system. The study was conducted in collaboration with Dr. Mauro Maccarrone, professor and chair of biochemistry at the Department of Biotechnological and Applied Clinical Sciences at the University of L’Aquila in Italy. “This peer-reviewed study provides important scientific research investigating the distinctly different physiological effects of rare cannabinoids,” said InMed Pharmaceuticals senior VP of preclinical research and development Dr. Eric Hsu in the press release. “As we continue to expand our portfolio of rare cannabinoids, including THCV and CBC, evidence-based research is imperative to improving our understanding of their biological activity. There is growing interest in the potential benefits of rare cannabinoids and this study represents InMed’s commitment to contributing to the body of research of rare cannabinoids.”

To view the report, visit https://cnw.fm/yJy9P

To view the full press release, visit https://cnw.fm/U1F9I

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary BayMedica LLC, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and is dedicated to delivering new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, please visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Kaival Brands (NASDAQ: KAVL) Reaches Agreement with Philip Morris

June 15, 2022 12:27:51

Kaival Brands (NASDAQ: KAVL), the U.S. distributor of all products manufactured by Bidi Vapor LLC, which are intended for legal-age nicotine users, has inked an international licensing agreement with Philip Morris Products S.A. (“PMPSA”) for the development and distribution of electronic nicotine delivery system (“ENDS”) products. Philip Morris Products is a wholly owned affiliate of Philip Morris International Inc. (NYSE: PM), and the agreement, which was finalized on June 13, 2022, covers products for markets outside of the United States. According to the announcement, the agreement between Kaival and PMPSA grants the latter the rights to manufacture, promote, sell and distribute Bidi Vapor’s premium ENDS device, the BIDI(R) Stick, in international markets outside the United States; the agreement extends the same rights to any potential new devices that are developed. The agreement could significantly expand international reach of Bidi Vapor technology and formulations. PMPSA noted that the agreement allows the company to broaden its current smoke-free product portfolio for adults desiring to continue smoking or using other nicotine products. “We, along with PMI and Bidi Vapor share the vision of a smoke-free future,” said Kaival Brands CEO Niraj Patel in the press release. “The BIDI Stick offers legal-age nicotine users a high-quality alternative to cigarettes that satisfies their taste preferences. Further, we, along with Bidi Vapor, are committed to prioritizing the appropriate regulation and responsible commercialization, inclusive of taking the necessary measures to make sure these products do not appeal to unintended audiences, including youth. By example, Bidi Vapor does not engage in direct online sales to consumers and requires age-verification contracts with our distributors and retailers. While Bidi Vapor continues to pursue the U.S. Food and Drug Administration premarket tobacco product authorization, cooperation with a major multi-national company like PMI, a leader in scientifically substantiated smoke-free products, opens doors on a global scale. Kaival Brands looks forward to a long productive relationship with PMI, to accelerate the end of smoking.”

To view the full press release, visit https://ibn.fm/OwpNN

About Kaival Brands Innovations Group Inc.

Based in Grant, Florida, Kaival Brands is a company focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets. The company’s vision is to develop internally, acquire, own or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. Kaival Brands is the exclusive global distributor of all products manufactured by Bidi Vapor. For more information about the company, visit www.KaivalBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to KAVLD are available in the company’s newsroom at http://ibn.fm/KAVL

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

GreenBox (NASDAQ: GBOX) Collaborates to Launch Digital Payment Solutions in American Samoa

June 15, 2022 12:25:41

GreenBox (NASDAQ: GBOX), a financial technology company that leverages proprietary blockchain security and token technology to deliver customized payment solutions, today announced the launch of its platform with Territorial Bank of American Samoa (“TBAS”). According to the update, the platform will provide digital payment solutions for businesses and consumers in American Samoa. “Digital transformation of payment solutions on the island is a key building block of Territorial Bank’s five-year strategic plan to modernize the banking sector in American Samoa and across the Pacific Islands. GreenBox’s technology will help realize that,” said Owen Peery, vice president and chief operations officer of Territorial Bank of American Samoa. “Territorial Bank is working closely with GreenBox POS on several related projects, all geared toward transitioning the island from a cash-based economy to a fully digital economy. The team at GreenBox has been exceptional to work with, and we look forward to a successful deployment of GreenBox’s platform and much-improved payment experience for our customers.”

To view the full press release, visit https://ccw.fm/8ARau

About GreenBox POS

GreenBox is an emerging financial technology company leveraging proprietary blockchain security and USD-pegged stablecoin token technology to build customized payment solutions for merchants and consumers. Founded in 2017 in San Diego, GreenBox’s applications enable an end-to-end suite of turnkey financial products, fraud detection and improve the efficiency of handling large-scale commercial processing volumes. The GreenBox platform offers a number of distinct advantages over traditional payment technologies including greater security and data privacy, enhanced identity theft protection and rapid speed to settlement. As a result, the GreenBox platform can log immense volumes of immutable transactional records in real-time for tier-1 partners around the globe. For more information, visit the company’s website at www.GreenBoxPOS.com.

NOTE TO INVESTORS: The latest news and updates relating to GBOX are available in the company’s newsroom at https://ccw.fm/GBOX

About CryptoCurrencyWire (“CCW”)

CryptoCurrencyWire (CCW) is a financial news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with CCW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, CCW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CCW brings its clients unparalleled visibility, recognition and brand awareness.

To receive instant SMS alerts, text “CRYPTO” to 844-397-5787 (U.S. Mobile Phones Only)

CryptoCurrency News Wire is where News, content and information converge via Crypto.

For more information, please visit https://www.CryptoCurrencyWire.com

Please see full terms of use and disclaimers on the CryptoCurrencyWire (CCW) website applicable to all content provided by CCW, wherever published or re-published: http://CCW.fm/Disclaimer

CryptoCurrencyWire (CCW)
New York, New York
www.CryptoCurrencyWire.com
212.994.9818 Office
[email protected]

CryptoCurrencyWire is part of the InvestorBrandNetwork

Aditxt’s (NASDAQ: ADTX) AditxtScore(TM) Added to PMLS Menu of Testing Services

June 15, 2022 12:24:59

Premier Medical Laboratory Services (“PMLS”), a nation-leading advanced medical diagnostics lab, today announced that it has added Aditxt’s (NASDAQ: ADTX) AditxtScore(TM) to its menu of testing services. AditxtScore provides more clarity regarding a patient’s individual immunity profile and allows patients to know their level of protection that an immune response to the virus or vaccination has provided them. “As new variants emerge, we want to equip physicians with the most advanced tests that allow a comprehensive view of their patient’s health status,” said Kevin Murdock, CEO of Premier Medical Laboratory Services. “With AditxtScore, individuals can make more informed decisions about whether vaccination, boosters or other risk mitigation strategies are the right course of action for them.”

To view the full press release, visit https://ibn.fm/L7U9z

About Aditxt Inc.

Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies. For more information, please visit www.Aditxt.com and www.AditxtScore.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Cepton (NASDAQ: CPTN) to Join Russell 3000(R) Index

June 15, 2022 12:24:31

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance MMT(R) lidar solutions, today announced that it will be added as a member of the Russell 3000(R) index at the conclusion of the 2022 Russell indexes annual reconstitution. This is effective after the U.S. market opens on June 27, 2022, according to a preliminary list of additions posted on June 3, 2022. “Cepton is excited to be joining the Russell 3000(R) index as it enables us to expand awareness of our story among the investment community as we continue to execute against our milestones generating long-term stakeholder value,” said Jun Pei, Cepton’s co-founder and CEO. “At Cepton, our design philosophy and technology enabled us to win the largest ADAS series production award to date, and inclusion in the Russell indexes is another point of validation in our ongoing journey as a public company.”

To view the full press release, visit https://ibn.fm/ZfBbH

About Cepton Inc.

Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented Micro Motion Technology (“MMT(R)”), Cepton aims to take lidar mainstream and achieve its vision of safe and autonomous transportation for everyone. Cepton has been awarded the largest known ADAS lidar series production award in the industry to date, based on the number of vehicle models awarded, to support General Motors’ Ultra Cruise program. Cepton is also engaged with all other Top 10 global OEMs. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to automotive customers in the Metro Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information, visit the company’s website at www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Aditxt’s (NASDAQ: ADTX) AditxtScore(TM) Provides Data Needed for Informed Decisions on COVID-19

June 14, 2022

June 14, 2022 13:12:39

Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system.
The company’s AditxtScore(TM) for COVID-19 generates an AditxtScore(TM), which offers a detailed profile of a person’s immune response for SARS-CoV-2, allowing consumers and their physicians to understand, manage, and monitor their level of immune response to the virus, thus allowing them to make informed health decisions
Aditxt’s platform is initially focusing on SARS-CoV-2, the virus that causes COVID-19, in recognition of the importance of immune monitoring and profiling in determining the course of action related to the virus.

Though the COVID-19 pandemic is now in its third year, as noted in a recent Scientific American article (https://ibn.fm/owGS8), scientists are still unsure whether there is a measure that could tell if people are protected from the virus. Still, different measures, collectively known as “correlates of protection,” define the immune response that a vaccine or viral infection would have to trigger to protect an individual from future infection. Two of these measures, neutralizing antibodies and T cells, are instrumental in immune profiling, a process that seeks to identify a person’s specific immune responses to the virus.

And as a 2021 journal article discussing immune profiling of COVID-19 writes: “Variability in the host immune response is likely to play a major role in determining the course of SARS-CoV-2 infection. Given this, there is a need to apply immune profiling to better understand the interaction of this virus with the…

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Lexaria Bioscience (NASDAQ: LEXX) and the Budding Alternative Nicotine Market

June 14, 2022

June 14, 2022 13:11:30

The nicotine pouch market is projected to reach $21.84 billion in 2027, up from $2.33 billion in 2020, representing a CAGR of 30.7%
The smokeless tobacco products sector is expected to post a CAGR of 7.2% over the forecast period (2018-2025)
Lexaria, through its patented DehydraTECH technology, is tapping into this important alternative nicotine sector
Its management is confident that its research and technology development investment will pay off and provide greater consumer satisfaction.

In 2019, it was estimated that at least 1.1 billion people globally smoked cigarettes regularly. 780 million, representing 71% of the global smoking population, noted that they wanted to quit. Their resolve to quit smoking has seen a significant decline in cigarette sales and a steady rise in nicotine alternatives, which experts project will carry on for the foreseeable future (https://cnw.fm/UyBtW).

For one, the nicotine pouch market has grown significantly and is estimated to reach $21.84 billion in 2027, up from $2.33 billion in 2020, representing a CAGR of 30.7%. The nicotine replacement therapy…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Spike in COVID Underscores Potential of Aditxt’s (NASDAQ: ADTX) Immune Monitoring Tech

June 13, 2022 12:05:59

Biotech innovation company Aditxt, Inc. is a Richmond, VA based company focused on developing and commercializing technologies to monitor and reprogram the immune system with the ultimate goal of improving patient outcomes for a variety of conditions ranging from seasonal allergies to organ transplant rejection
Aditxt’s first commercial product, AditxtScore(TM), helps patients obtain data relating to COVID-19 infection and vulnerability
While immunization rates and the seasonal reduction of COVID infections have spurred optimism about enjoying normal public activities, a recent spike in COVID infections has led national health officials to again warn Americans to not become complacent about the pandemic
Health officials also recently acknowledged evidence that COVID-related deaths have now exceeded 1 million in the United States alone, making the country’s total the highest in the world

Johns Hopkins University announced in May that COVID-19-related deaths in the United States had surpassed 1 million just over two years after the outbreak of the worldwide pandemic, the highest recorded national death toll from COVID, while media reports acknowledged that the difficulty of precisely tracking COVID infections means the 1 million mark may have been passed “days or months earlier” (https://ibn.fm/W6f7J).

While local communities nationwide have mostly seen falling COVID infections rates during the warming climate and residents have been further encouraged by vaccination campaigns to enjoy public activities…

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Cybin (NEO: CYBN) (NYSE American: CYBN) Awarded Board Approval for CYB003 Phase 1/2a Trial

June 13, 2022 12:05:00

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, received Institutional Review Board (“IRB”) approval to begin its planned phase 1/2a clinical trial. The trial, the first-in-human phase 1/2a trial evaluating CYBN’s proprietary deuterated psilocybin analog CYB003, is slated to begin in mid-2022.The study will evaluate CYB003 for the treatment of major depressive disorder (“MDD”). Cybin applied for IRB approval just last month. According to the announcement, Cybin wholly owned subsidiary Cybin IRL Limited has partnered with Clinilabs Drug Development Corporation to conduct the randomized, double-blind, placebo-controlled study. The study involves participants receiving two administrations of the substance, along with a response/remission assessment at week 3 and week 6. In addition, participants will be offered an optional open-label follow-up study lasting up to 12 weeks. Clinilabs is a global, full-service contract research organization that has built a reputation for expertise in central nervous system drug development. “IRB approval of our trial protocol is a significant regulatory milestone for CYB003 as it leads us one step closer to potentially providing this important treatment option to people in need,” said Cybin CEO Doug Drysdale in the press release. “The team has worked tirelessly to move this program into the clinic, and we look forward to initiating the study in mid-2022 and further supporting our mission to develop psychedelics into therapeutics.”

To view the full press release, visit https://ibn.fm/YL08O

About Cybin Inc.

Cybin is a leading ethical biotechnology company, working with a network of world-class partners and internationally recognized scientists and on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, and novel formulation approaches and treatment regimens for mental-health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Flora Growth’s (NASDAQ: FLGC) Completion of Key Milestones Position It for Success

June 13, 2022 12:04:28

Flora Growth Corp. (NASDAQ: FLGC) recently announced financial and operating results for the 2021 fiscal year that show the success of its efforts as revenues and profits begin what is expected to be a rapid climb. “The year-end financial results show about $9 million in revenues, which is ‘significantly higher’ than those reported the prior year before the law change and Flora’s IPO launch on the Nasdaq Capital Market. The report maintains the company’s outlook for ending 2022 with revenues of $35 million to $45 million, which would be growth of between 288% and 400% over 2021. Much of Flora’s momentum is driven by its acquisition of consumer wellness brand JustCBD, which increased Flora’s profile to more than half a million consumers through 14,000 retail stores in the United States,” reads a recent article. “We are proud of the milestones we achieved in 2021, including the completion of key strategic infrastructure projects, the strengthening of our balance sheet and the deployment of our M&A strategy,” CEO and Chairman Luis Merchan stated. “The completion of our cultivation and extraction facilities has positioned Flora for success in this rapidly evolving industry, as we satisfied the requirements for the cultivation, transformation and export of up to 43.6 tons of THC cannabis flower.”

To view the full article, visit https://cnw.fm/xYV8r

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands delivering the most compelling customer experiences in the world, one community at a time. As the operator of one of the most extensive outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands and life sciences divisions. Visit www.FloraGrowth.com or follow @floragrowthcorp on social media for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Golden Matrix (NASDAQ: GMGI) Poised as Most Extensive Gaming Portfolio Provider

June 13, 2022 12:03:57

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, has sought to bridge the gap between gaming operators and studios through its GM-X and the launch of its B2B aggregate gaming system, GMX-Ag. “Golden Matrix’s GM-X system has long been established as the industry standard, granting gaming platforms with access to upwards of 10,000 games from a broad array of over 25 gaming studios via a singly gaming API – firmly cementing its position as the industry’s most extensive gaming portfolio provider. The company’s partners dominate the global online gaming market, with GMGI currently supporting over 500 unique casino brands and over 6 million players. Now and through the launch of its next-generation GMX-Ag platform, Golden Matrix is seeking to further establish its position as the industry’s online gaming aggregator of choice,” a recent article reads. “More recently, Golden Matrix Group announced that it would aggregate Spearhead Studio’s online casino video games within its product portfolio, through the formation of a ‘pivotal’ alliance with the gaming studio. The agreement will see Spearhead Studio’s portfolio of over 90 proprietary video games… accessible by way of Golden Matrix’s online casino offering.”

To view the full article, visit https://ibn.fm/XNDw0

About Golden Matrix Group Inc.

Golden Matrix Group, based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds configurable and scalable white-label B2B gaming platforms for its international customers, located primarily in the Asia Pacific region. The gaming IP includes tools for marketing, acquisition, retention, and monetization of users. The company’s platform can be accessed through both desktop and mobile applications. As a result of its 80% controlling ownership interest in UK-based RKings Competitions Ltd., Golden Matrix also generates revenues from RKings’ scalable B2C tournament platform. Golden Matrix’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with current U.S. law. For more information about the company, visit www.GoldenMatrix.com.

NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Knightscope (NASDAQ: KSCP) Robot Roadshow to Take Spotlight at Kennedy Space Center

June 13, 2022 12:03:12

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, announced that its Robot Roadshow will land in Florida at the Kennedy Space Center from 10 a.m. to 2 p.m. ET on June 17, 2022. The Robot Roadshow is an engaging experiential event designed to grab attention, forge direct connections with potential clients, and strike up conversations in a compelling fashion.

The announcement reads, “The Robot Roadshow has completed 45 landings in 16 states and Washington, D.C. to date. Knightscope’s crime-fighting robots tour the U.S. in a space-age, NASA-like ‘pod’ allowing attendees to experience all the technology that is enabling these Autonomous Security Robots (‘ASRs’) to help make sites safer today from Hawaii to Texas to North Carolina. A short video of a past event hosted by the Los Angeles Police Department may be viewed here: https://vimeo.com/645787920.”

There is no charge to participate in or visit the Roadshow. However, available slots fill up quickly. Appointments are recommended and can be made by visiting the following link: https://calendly.com/robotroadshow/

To view the full press release, visit https://ibn.fm/mOta4

About Knightscope

Knightscope is an advanced security technology company based in Silicon Valley that builds fully autonomous security robots that deter, detect and report. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information, visit the company’s website at www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Flora Growth (NASDAQ: FLGC) Adding to Cannabis Product Line, Research

June 8, 2022

June 8, 2022 15:53:45

Flora Growth is building on its cannabis brand globalization efforts with two partnerships that expand its product portfolio and its research efforts in the United States and United Kingdom
Flora’s partnership with former NFL athlete Ricky Williams has delivered its first product — a cannabis one-hitter accessory designed to provide a unique experience emblematic of Williams’ active lifestyle brand
The company’s acquisition of the Masaya CBD brand developed by a cell biologist on Flora’s board of directors gives the company a formulation suitable for its current clinical trial efforts in the United Kingdom, and a well-received brand designed to help seizure patients
Flora’s cultivation operations are centered at its Colombia facility, and recent regulatory changes there have made it easier for Flora to supply its brands in the United States and elsewhere

On the heels of a year in which global cannabis market brand-builder Flora Growth (NASDAQ: FLGC) saw rapid expansion of its cultivation, manufacturing and distribution operations that support the company’s business divisions for cosmetics, hemp textiles and food and beverage products, Flora is increasing its offerings by bringing a promising CBD brand into its fold and introducing a new product for quality cannabis experiences.

The acquisition of cell biologist Dr. Annabelle Manalo-Morgan’s Masaya brand gives Flora Growth its first offering under its Flora Life Sciences division as well as a patent-pending formulation for use in Flora’s…

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]

CBDWire is part of the InvestorBrandNetwork.

Lexaria (NASDAQ: LEXX) Grants DehydraTECH(TM) License to AnodGen Bioceuticals

June 8, 2022

June 8, 2022 15:53:22

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the awarding of a five-year, non-exclusive DehydraTECH(TM) license from its wholly-owned subsidiary, Lexaria Pharmaceutical Corp., to AnodGen Bioceuticals of Ireland. According to the update, the awarded license is valid for the manufacturing and distribution of DehydraTECH-processed cannabinoid active pharmaceutical ingredient (“API”) powders within Europe including the U.K., Australia and New Zealand; including pharmaceutical and medical product applications for psychoactive cannabinoids and medical product applications for non-psychoactive cannabinoids. AnodGen, which has the right to manufacture and sell these API powders to third party companies for their own products designated by a national regulator as a medical product, drug, nutraceutical, pharmaceutical or biopharmaceutical, will pay royalty fees to Lexaria for all API powders sold that utilize the DehydraTECH technology. “This strategic alliance with Lexaria Bioscience Corp. underscores the focus of AnodGen to ‘Bring Science to Life,’ in addition to our research and APIs,” said Dr Slimane Aboulkacem, chairman and founding member of AnodGen Bioceuticals.

To view the full press release, visit https://cnw.fm/i8kzk

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

SRAX’s (NASDAQ: SRAX) Event to Highlight Companies in Decentralized Web Space

June 8, 2022

June 8, 2022 15:52:51

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, today announced that the Sequire Decentralized Web Conference will take place on June 23, 2022. As blockchain, DAOs, NFTS and digital currencies take off around the world with far-reaching potential, SRAX is bringing together a list of influential companies making history in this sector for a full day of presentations. Nearly nine million active small-cap investors were invited to the event, which will feature over 15 decentralized web focused companies and keynotes highlighting prominent names in this space. “We’re excited about this year’s Decentralized Web event because of the continued innovation we’re seeing in the industry,” said Morgan Fogg, vice president of community and events at SRAX. “Last year our focus was specifically on blockchain and crypto, and this year we’re expanding to invite the top experts and companies in the entire decentralized web space.”

To view the full press release, visit https://ibn.fm/Eu4Vi

About SRAX Inc.

SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Cybin (NEO: CYBN) (NYSE American: CYBN) Acquires Entheon’s DMT Clinical Study

June 7, 2022 14:51:55

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has entered an agreement to acquire the largest phase 1 DMT study conducted to date. The acquisition, conducted through Cybin IRL Limited, a wholly owned subsidiary of Cybin, is expected to accelerate Cybin’s CYB004 program timeline by an estimated nine months; CYB004 is Cybin’s proprietary deuterated DMT molecule designed for the potential treatment of anxiety disorders.. The phase 1 N,N-dimethyltryptamine (“DMT”) study is focused on evaluating pharmacokinetics/pharmacodynamics of DMT currently underway and is expected to significantly impact the clinical path forward. Renamed CYB004-E, the phase 1 EBRX-101 study is being conducted in the Netherlands at the site of a leading independent foundation, the Centre for Human Drug Research, which specializes in innovative early-stage clinical drug research; the study involves 50 healthy volunteers who smoke tobacco and is the largest phase 1 DMT clinical study conducted to date. The company is planning to replace its currently planned pilot study for CYB004 with this new study, and Entheon will serve as external consultants to Cybin. “The most precious commodity in drug development is time, and acquiring this robust phase 1 study already underway potentially accelerates the CYB004 development program by approximately nine months,” said Cybin CEO Doug Drysdale in the press release. “The PK findings from the CYB004-E study should also help to inform the clinical path forward for this innovative and proprietary molecule. This transaction also provides Cybin with access to a world-class research foundation and the privilege to work with the Entheon team, who offer a wealth of knowledge and expertise in this psychedelic class. . . . With our recent IND filing for CYB003, we are quickly becoming a multiprogram clinical-stage company with four sponsored human trials underway in 2022. This is especially meaningful to our work to bring our innovative psychedelic-based therapies to people in need as quickly as possible. This is a truly exciting time for Cybin.”

To view the full press release, visit https://ibn.fm/i1eGI

About Cybin Inc.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Mullen Automotive (NASDAQ: MULN) Added to Russell 2000(R), 3000(R) Indexes

June 7, 2022 14:51:14

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, will be joining the Russell 2000 and 3000® Indexes effective later this month, on June 27, 2022, after the market opens. The company was named on a preliminary list of additions posted by FTSE Russell on June 3, 2022. In addition, MULN will be automatically added to the appropriate growth and value indexes. According to the announcement, the Russell indexes are comprised of the 4,000 largest U.S. stocks, based on May 6, 2022, trading status. Membership is for one year and is reassessed every year, with new members released annually. Membership in the Russell 3000 Index constituted automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index along with other growth and value style indexes as appropriate. The index identifies members based primarily on objective, market-capitalization rankings and style attributes. “The inclusion of Mullen Automotive shares in the Russell 2000 and 3000 Indexes, which are some of the stock market’s top performance benchmarks, is a great honor,” said Mullen Automotive CEO and chair David Michery in the press release. “I believe that our inclusion in the Russell Indexes will bring Mullen Automotive great visibility within the institutional investment community. This is an excellent milestone for our Company, which will provide increased liquidity and investor awareness.”

For more information, view the full press release

About Mullen Automotive Inc.

Mullen is a southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Lexaria (NASDAQ: LEXX) Takes First Regulatory Step for DehydraTECH-CBD for Hypertension

June 7, 2022 14:50:48

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has successfully filed a pre-Investigational New Drug (“IND”) meeting request letter with the U.S. Food and Drug Administration (“FDA”). According to the update, the FDA has already responded to and confirmed Lexaria’s filing and has provided a target date of July 30, 2022, subject to certain conditions being met. “We are excited to take this important first regulatory step with the FDA for the development of our DehydraTECH-CBD for the treatment of hypertension,” said John Docherty, president of Lexaria. “Submission of this request letter initiates formal communication with the FDA regarding our IND clinical trial plans, in order to help define the critical path for clinical development and marketing approval of our potentially very significant new hypertension therapeutic.”

For more information, view the full press release

About Lexaria Bioscience Corp.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Aditxt’s (NASDAQ: ADTX) Immune Monitoring Platform ‘Is the Right Tech at the Right Time’

June 7, 2022 14:49:56

Aditxt (NASDAQ: ADTX) recently entered into a multi-year partnership with Guthy-Renker LLC- affiliated GRS. The partnership focuses on building awareness and visibility among consumers and health care providers for the proprietary AditxtScore(TM) Immune Monitoring Platform. “AditxtScore is the right technology at the right time. Our first application, AditxtScore for COVID-19, delivers timely reports on vulnerability and immune status to SARS-CoV-2 and its known variants, giving consumers and their physicians the data they need to make informed health decisions for themselves and their families,” Aditxt CEO and Co-Founder Amro Albanna was quoted in a recent article. Albanna added that the company’s Richmond, Virginia-based AditxtScore Immune Monitoring Center is fully operational and designed to support increased demand for the company’s products and services. GRS President Boris Shimanovsky also commented on the partnership, underlining that AditxtScore provides a more detailed profile of the immune system, allowing individuals to understand, manage and monitor their immunity profiles.

To view the full article, visit https://ibn.fm/qEpLi

About Aditxt Inc.

Aditxt is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. Aditxt’s immune mapping technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies. For more information, please visit www.Aditxt.com and www.AditxtScore.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Knightscope (NASDAQ: KSCP) Earns “In-Process” Rating from US FedRAMP Program

June 7, 2022 14:49:23

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies committed to enhancing U.S. security operations, announced that as part of its efforts to pursue Authority to Authorize (“ATO”) in the Federal Risk and Authorization Management Program (“FedRAMP”), the company achieved “In-Process” status. A government-wide program that promotes the adoption of secure cloud services across the federal government, FedRAMP provides a standardized approach to security assessment and authorization, and provides continuous monitoring for cloud products and services.

Knightscope has been working to design a secure, hardened environment specifically to support government clients; as part of those efforts, the company built a strictly controlled version of Knightscope’s product offering, which was tested by a FedRAMP authorized third-party assessment organization using state-of-the-art cyber technologies. The company noted that only 262 organizations with cloud-based services have earned Authority To Operate (“ATO”) recognition, with only 83 of those having reached the in-process level.

“One of the key roles of government is to protect its citizens, so it is critical that we provide them with the most advanced public safety technologies available,” said Knightscope EVP and chief intelligence officer Mercedes Soria in the press release. “The FedRAMP process is arduous, but we believe it is a great investment of time and resources as it ensures our cybersecurity efforts are top notch. I’m looking forward to continuing to build even more cutting-edge technology to support our mission to make America the safest country in the world.”

For more information, view the full press release

About Knightscope Inc.

Knightscope is an advanced security technology company based in Silicon Valley that builds fully autonomous security robots that deter, detect and report. The company’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to Knight are available in the company’s newsroom at https://ibn.fm/Knight

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

InMed Pharmaceuticals (NASDAQ: INM) Closes $5M Direct, Private Placement Offerings

June 7, 2022 14:48:53

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has closed on its registered direct offering and concurrent private placement with a single healthcare-focused institutional investor; the offerings were priced at-the-market under Nasdaq rules. According to the announcement, for the registered direct offering, INM issued 4,079,256 common shares at a purchase price of $0.858 per share (or prefunded warrant in lieu thereof). For the concurrent private placement, InMed issued and sold to the investor 1,748,250 common shares (or prefunded warrant in lieu thereto); those shares were offered at the same purchase price as those associated with the registered direct offering. InMed noted that it also issued unregistered preferred investment options to the investor; those investment options allowed for the purchase of up to 5,827,506 common shares. The announcement also outlined amendments to existing warrants that had been previously issued to the same investor. According to the announcement, the company could see gross proceeds from both offerings reach an estimated $5 million. InMed anticipates using the net proceeds from the offerings to continue pipeline development and advance commercial activities as well for general working capital purposes.

To view the full press release, visit https://cnw.fm/91OXR

About InMed Pharmaceuticals Inc.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Mullen Automotive (NASDAQ: MULN) CEO to Appear on Benzinga’s ‘All Access’ Series

June 6, 2022 10:16:28

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, and its CEO and chair David Michery are spotlighted during an interview on Benzinga’s All Access Series. The interview is slated for today, June 3, 2022, at 11 a.m. ET. Michery and All Access host Spencer Israel will discuss the company, including its upcoming “Strikingly Different” U.S. test drive tour, which will include stops at 19 cities across the country. Benzinga’s All Access show is a valuable source for those who want to learn more about the latest-trending stocks and investment opportunities. The show features live CEO interviews, due diligence presentations and Q&As with company leaders. “I invite everyone to join us tomorrow on the interview with Benzinga,” said Mullen CEO and chair David Michery in the press release. “The Benzinga All Access Series is a great opportunity for everyone to listen in and hear the latest from me on Mullen’s EV efforts.”

To view the full interview, visit https://ibn.fm/o5DVz

To view the full press release, visit https://ibn.fm/7xY1D

About Mullen Automotive Inc.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Cybin’s (NEO: CYBN) (NYSE American: CYBN) EMBARK Spotlighted in “Frontiers in Psychology”

June 6, 2022 10:15:53

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its proprietary EMBARK program is the focus of a recent article in the “Frontiers in Psychology” journal. The peer-reviewed article discusses the company’s model of psychedelic-assisted psychotherapy that integrates leading clinical approaches to promote effective facilitation and supportive healing with psychedelic medicines. Titled “Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model,” the article appears in the June 2, 2022, issue of the publication, which is the largest journal in the field of psychology. The article discusses EMBARK’s six clinical domains (existential-spiritual, mindfulness, body aware, affective-cognitive, relational and keeping momentum) and reviews the strengths and limitations of existing psychedelic-assisted psychotherapy approaches and evidence-based therapies. In addition, the company also announced it has created a 28-member team of faculty and advisors who will lead the company’s EMBARK Psychedelic Facilitator Training Program. Recognized leaders in their field, the team members will oversee Cybin’s innovative new program. “It’s a pleasure to see our work published in this respected journal,” said Cybin chief clinical officer and EMBARK cocreator Alex Belser in the press release. “In developing EMBARK, we looked at 17 models of psychedelic-assisted psychotherapy, and we noticed that many are missing critical elements: a focus on ethics, on human relationships, on the body as a site of somatic healing, and on evidence-based practices. We designed EMBARK to overcome some of these limitations as an integrative model of psychedelic therapy. We’d like to honor the contributions of many teachers and leaders in the field who have helped chart this course.”

To view the full article, visit https://ibn.fm/2mwT8

To view the full press releases, visit https://ibn.fm/Z5lol and https://ibn.fm/UdIRE

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Lexaria (NASDAQ: LEXX) Awards Exclusive License to Japan’s Premier Wellness Science Co.

June 6, 2022 10:15:16

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has awarded licensing of its proprietary DehydraTECH(TM) offering for development in Japan to Premier Wellness Science Co. Ltd, a wholly owned subsidiary of Premier Anti-Aging Co. Ltd. LEXX announced that Premier is purchasing exclusive rights to DehydraTECH technology for the Japanese nonpharmaceutical market; the company will use the tech in oral liquid and nonliquid products, as well as for topical, hair-care, lip-care and cosmetics products. According to the announcement, Lexaria will receive minimum payments of $4,527,500 over the next five years, as all well as royalties from the sales of products made with DehydraTECH, which the company anticipates could be significantly greater than the minimum payments. In addition, the two companies agreed to explore the possibility of R&D collaborations. An official from Premier noted that the company partnered with Lexaria based on DehydraTECH’s superior performance and the extensive data available through Lexaria’s years of testing. “Lexaria is delighted to be working with Premier Wellness Science, which we expect will dominate the newly opening Japanese market for CBD-based products,” said Lexaria CEO Chris Bunka in the press release. “Premier and Lexaria share similar philosophies, such as the provision of world-leading products created through scientific advantages and placing the consumer’s needs ahead of our own. We could not have found a better partner with which to introduce DehydraTECH-enabled products to the Japanese markets.”

For more information, view the full press release

About Lexaria Bioscience Corp.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Golden Matrix Group (NASDAQ: GMGI) Announces Strong Q2 Financial Results

June 6, 2022 10:14:40

Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, today announced financial results for its second fiscal quarter ended April 30, 2022. Among the highlights, the company reported Q2 revenues of $8,482,743, a 221% increase as compared to the same quarter last year. The company also noted 15 consecutive quarters of profitability. “We are pleased with the financial results of our second quarter as a company with both B2B and B2C verticals,” said Golden Matrix CEO Brian Goodman. “During the quarter we implemented upgraded technology and stronger accounting controls to improve cash flow and profitability at RKings. With the Tournament Platform’s added features and functionality, we expect steady increases in both the monthly number of skill tournaments and participants; and, because this robust platform gives RKings’ tournament players immediate access to a growing number of exciting prize competitions, we expect this third quarter and future quarters to generate increasing revenues and profits.”

For more information, view the full press release

About Golden Matrix Group Inc.

NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

SRAX (NASDAQ: SRAX) Announces Details for 2022 LD Micro Invitational

June 6, 2022 10:14:18

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, today announced details for the 2022 LD Micro Invitational. SRAX will host the prominent investor conference on June 7-9 at the Four Seasons Hotel Westlake Village, as well as via its Sequire Virtual Events platform. LD Micro is the host of the most influential conferences in the small-cap world. Following last October’s success of the LD Micro Main Event, SRAX is providing a virtual option for those unable to attend the physical conference. The event, which expects to feature over 200 companies and several influential keynotes, will focus on newcomers and, in the words of LD Micro Founder Chris Lahiji, will introduce companies on the “cusp” of doing big things. Interested parties should visit https://www.meetmax.com/sched/event_82067/conference_home.html to apply for the invitation-only, in-person event and https://ldinv12.mysequire.com/ to register to attend the virtual conference.

For more information, view the full press release

About SRAX Inc.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Flora Growth (NASDAQ: FLGC) Bolsters Expansion with Cannabis Vet Holly Bell’s Appointment

June 6, 2022 10:13:47

Flora Growth has appointed regulatory veteran Holly Bell as the new Vice President of Regulatory Affairs
Bell will help further the company’s domestic and global expansion strategy and lead government relations in key international markets
She will also oversee the regulatory strategy supporting the advancement of the company’s cultivation, distribution, and pharmaceutical programs
Bell also participated in the first event in her new position- the Florida Industrial Hemp Conference and Exhibition held on May 20-22, 2022

In recent months, Flora Growth (NASDAQ: FLGC) has been on an aggressive international expansion plan that has seen exports to Mexico and Spain, with an established presence in the U.K. and E.U.

In a move to strengthen the company’s global expansion strategy further, Flora Growth recently announced the appointment of regulatory veteran Holly Bell as the new Vice President of…

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

InMed Pharmaceuticals (NASDAQ: INM) Announces $5M Registered Offerings

June 3, 2022

June 3, 2022 11:41:03

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced its entry into securities purchase agreements with a single health care-focused institutional investor for the issuance and sale of 4,079,256 of its common shares, each at a purchase price of $0.858 (or pre-funded warrant in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, InMed has also agreed to issue and sell to the investor 1,748,250 common shares (or pre-funded warrant in lieu thereto) at the same purchase price as in the registered direct offering. In addition, the company has agreed to issue to the investor in the offerings unregistered preferred investment options to purchase up to an aggregate of 5,827,506 common shares. The company expects aggregate gross proceeds of approximately $5 million through both offerings, which are expected to close on or about June 6, 2022, subject to the satisfaction of customary conditions. InMed intends to use the net proceeds to continue pipeline development, advance commercial activities and for general working capital purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings.

To view the full press release, visit https://cnw.fm/VSwXH

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary BayMedica LLC, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is also a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com and www.BayMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Cybin (NYSE American: CYBN) (NEO: CYBN) to Host Webinar Delving into Psychedelics

June 3, 2022

June 3, 2022 11:40:35

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that it will host a virtual Key Opinion Leader webinar from 11:00 a.m. to 12:00 p.m. ET on Thursday, June 9, 2022. The webinar will be moderated by Cybin’s Chief Executive Officer Doug Drysdale and will feature two leading experts for a discussion on the psychedelics landscape and current and emerging psychedelic-based therapeutics. Dr. John Krystal, the Robert L. McNeil, Jr., Professor of Translational Research; Professor of Psychiatry, Neuroscience and Psychology; Chair of the Department of Psychiatry at Yale University; and Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital, will be included in the discussion. Also featured will be Dr. David Nutt, DM, FRCP, FRCPsych, FMedSci, DLaws, the Edmund J. Safra Professor of Neuropsychopharmacology, Head Centre for Psychedelic Research in the Division of Brain Sciences, Imperial College London. Interested parties should visit https://ibn.fm/EkkdK to register for the event and access the webcast. In addition, the archived version of the webcast will be available on the company’s investor relations website.

To view the full press release, visit https://ibn.fm/eDVTh

About Cybin Inc.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Lexaria’s (NASDAQ: LEXX) DehydraTECH Footprint Extends to Europe with Valcon Medical License

June 3, 2022

June 3, 2022 11:40:04

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has awarded licensing of its proprietary DehydraTECH(TM) offering for development in the European and United Kingdom markets. The company awarded the nonexclusive licenses to Valcon Medical A/S, a European contract manufacturing organization that specializes in the manufacturing of medical cannabis extracts for the EU and UK. According to the announcement, Lexaria will receive milestone fees and royalty payments from sales of products manufactured by Valcon.Valcon products will include an array of options, from nonregistered medical products through magistral programs to country-level market-authorized medical cannabis products through pilot programs; they will also include bulk powders or solid oral-dosage forms as well as powder-filled capsules, compressed tablets, pills, oral melts, and topical creams and lotions. “We are very excited to have licensed Lexaria’s DehydraTECH technology for what we expect will be rapid growth across the European markets,” said Valcon Medical A/S CEO Pete Patterson in the press release. “As Valcon continues to build out its manufacturing capabilities, we are developing new IP and partnering with industry leaders. Lexaria has developed and patented an incredible technology, which will benefit medical cannabis patients with enhanced bioavailability with a quicker effect onset. Backed by substantial clinical efficacy studies, Valcon will bridge the extensive work that Lexaria has done in the U.S., over to Europe.”

To view the full press release, visit https://cnw.fm/ffrpT

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids and nicotine by up to 10 times and, in some instances, with cannabinoids by as much as 27 times compared to standard industry formulations; reduce time of onset from one to two hours to minutes; and mask unwanted tastes; it is also being evaluated for orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Mullen (NASDAQ: MULN) Announces Test Performance of Solid-State Battery

June 1, 2022

June 1, 2022 11:31:17

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced results of its solid-state polymer battery testing with the Battery Innovation Center (“BIC”) in Indiana. According to the update, BIC’s testing results show the solid-state polymer cell, rated at 300 Ah and 3.7 volts, tested in at 343.28 Ah at 4.2 volts, exceeding expectation and in line with test tolerance from previous EV Grid test results. Test data collected from both BIC and EV Grid demonstrate an impressive outcome and future for solid-state batteries. It is expected that with this technology, when scaled to the vehicle pack level, a 150-kilowatt hour solid-state battery can, on a full charge, deliver over 600 miles of range for the Mullen FIVE EV Crossover. “I’m impressed with the ongoing performance of the solid-state cell after going thru multiple intense testing sessions from accredited testing facilities,” said David Michery, CEO and chairman of Mullen Automotive. “The battery has performed exceptionally well, and I’m pleased with the results from BIC in Indiana.”

To view the full news release, visit https://ibn.fm/c4ue4

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Freight Technologies (NASDAQ: FRGT) Announces Name, Ticker Change

June 1, 2022

June 1, 2022 11:30:38

Freight Technologies (NASDAQ: FRGT) is now trading on the Nasdaq Market. Formerly known as Hudson Capital Inc. (NASDAQ: HUSN), the company changed its name and ticker effective May 27, 2022. According to the announcement, the company will continue to do business under its wholly owned subsidiary’s commercial name: Freight App Inc. (“Fr8App”). The Freight App platform combines technology and artificial intelligence to offer its cloud-based solutions suite that automates the over-the-road transportation process, ultimately decreasing the need for human touch points and reducing load booking time to minutes or even instantaneously. The suite includes Fr8app, a B2B marketplace powered by AI and machine learning that provides a real-time broker portal; Fr8Radar, which offers track-and-trace visibility in real time and all in one screen; Fr8TMS, a transportation management system; Fr8FMS, a fleet management system; Fr8Data, which offers real-time dashboards and reports to shippers and carriers; and Fr8Fleet, which offers private fleet management that enables large corporate shippers to purchase dedicated capacity. “As a hi-tech transportation logistics company 100% in North America, our new Freight Technologies moniker aptly creates a cohesive umbrella for all of our solutions,” said Fr8Tech CEO Javier Salgas in the press release. “In 2022, we are gaining traction as evidenced by our record monthly sales in April, and our positive trend in loads carried this year. We are executing our growth strategy and look forward to delivering in 2022 and beyond.”

To view the full press release, visit https://ibn.fm/NLKu3

About Freight Technologies Inc.

Freight Technologies is a North American transportation logistics technology platform company focused on U.S.-Mexico-Canada cross-border shipping. Its wholly owned subsidiary, Freight App Inc. (Fr8App), focuses on truckload freight, making shipping simple, transparent and efficient. Fr8App uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via innovative technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management and committed capacity solutions. For more information, please visit www.FR8Technologies.com.

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Cybin (NEO: CYBN) (NYSE American: CYBN) Reports on Ketamine Study

May 31, 2022 12:19:36

Study shows that COVID-19 pandemic has affected mental health of 59% of U.S. population, intensifying already-serious issue
CYBN-sponsored feasibility study indicates ketamine-induced changes in brain’s functional connectivity persisted for several days after receiving the substance
Kernel Flow pivotal in developing most accurate, effective treatment regimens for patients

The challenges associated with mental-health issues are rising, following the global pandemic. Already a serious problem before COVID-19, mental health has become even more pressing now, with many companies committed to offering relief to the nearly 1 billion people worldwide who deal with mental-health issues. Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to progressing psychedelics to therapeutics, is making major progress in that direction based on pilot results from a recent study evaluating a proprietary neuroimaging technology (https://ibn.fm/1vach).

“In our national survey on mental health and coronavirus, we found that the COVID-19 pandemic has affected the mental health of 59% of people in the United States,” reported a recent SingleCare article…

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Mullen Automotive (NASDAQ: MULN) Offering EVs with 600-Plus Mile Range

May 31, 2022 12:18:35

J.D. Power survey reports range was factor most cited in deciding what EV to buy
Mullen is making significant strides toward producing vehicles that feature some of the longest ranges available in the EV space
Recognizing the critical role of battery and range in the success of an EV, Mullen is exploring other advanced battery technologies

One of the challenges preventing enthusiastic acceptance of electric vehicles is range anxiety, fear that an electric car will run out of battery or fuel before the driver can reach their destination or a charging station. The concern is valid — a January 2022 Energy.gov study reported that the median rage for EV last year was 234 miles (https://ibn.fm/tvIzU). Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle manufacturer, is focused on improving that number; the company is currently actively testing advanced battery technology which can provide a range of 600-plus miles on a full charge at the pack level (https://ibn.fm/4H957).

“When modern all-electric vehicles (‘EV’) were introduced in model year (‘MY’) 2011, there were four models available with ranges spanning from 63 to 94 miles with a median range of 68 miles,” reports Energy.gov. “Over time, the number of models and the…

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Energy Stocks

Green Energy Stocks (GES) is a specialized communications platform with a focus on companies working to shape the future of the green economy. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the InvestorBrandNetwork (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GES is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GES brings its clients unparalleled visibility, recognition and brand awareness. GES is where news, content and information converge.

To receive SMS text alerts from Green Energy Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenNRGStocks.com

Please see full terms of use and disclaimers on the Green Energy Stocks website applicable to all content provided by GES, wherever published or re-published: https://www.GreenNRGStocks.com/Disclaimer

Green Energy Stocks
Los Angeles, CA
www.GreenNRGStocks.com
415.949.5050 Office
[email protected]

Green Energy Stocks is part of the InvestorBrandNetwork.

Flora Growth (NASDAQ: FLGC) Announces Launch of JustCBD Products on Amazon.co.uk

May 31, 2022 12:18:09

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that its wholly-owned subsidiary JustCBD will be launching its line of Novel Foods-registered CBD products on Amazon.co.uk. Since its entry into the now £700 million CBD market in October 2021, Amazon U.K. has expanded the initial pilot-only program to include vendors who have demonstrated compliance with U.K. CBD Novel Food regulations. Producers awarded U.K. Novel Food authorization must prove the product is safe for consumption and labeled correctly. “With health and wellness playing an increasingly important role in customers’ lives, we are excited to increase the selection of quality CBD products offered to Amazon customers in the U.K.,” said Hussein Rakine, CEO of JustCBD. “The JustCBD team looks forward to working closely with Amazon to expand our product offering to other countries as our partnership and brand presence in the United Kingdom grows.”

To view the full press release, visit https://cnw.fm/gtGhR

About Flora Growth Corp.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience (NASDAQ: LEXX) Leveraging DehydraTECH(TM) to Tap into Various Markets

May 31, 2022 12:17:43

Lexaria Bioscience Corp. (NASDAQ: LEXX) has been pushing the boundaries of drug delivery through its patented DehydraTECH(TM) technology, which has evidenced more efficient delivery of active pharmaceutical ingredients (“APIs”) into the bloodstream while also increasing their bioavailability. “Its technology has seen application in pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter capsules, pills, tablets, and oral suspensions. Lexaria has explored its usage in the delivery of cannabinoids, nicotine, antivirals, PDE5 inhibitors, and more,” a recent article reads. “All of Lexaria’s efforts serve to demonstrate the superior performance of both its research program and its DehydraTECH drug delivery technology. By doing so, it is looking to tap into various markets, including but not limited to oral cannabinoids, oral mucosal nicotine, antivirals, human hormones, dementia, rheumatoid disease, and diabetes. Lexaria’s management hopes that, before the end of the 2022 calendar year, it will have built sufficient data to effect meaningful industry progress and sustainable increases in valuation to steer the conversation forward and allow for the greater adoption of DehydraTECH.”

To view the full article, visit https://cnw.fm/ZbMED

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Golden Matrix Group (NASDAQ: GMGI) Eyeing Expansion

May 31, 2022 12:17:06

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, has historically focused on business-to-business (“B2B”) operations, providing gaming companies with the tools they need to improve profits and reduce churn, industry nomenclature for losing players. “Golden Matrix IP includes its flagship GM-X System and its recently released next-gen GM-Ag System that is regarded as the industry benchmark, delivering access to 10,000+ games from more than 25 providers,” a recent article reads. “Most of Golden Matrix’s business comes from the Asia Pacific, but management is looking to expand closer to home. In March, the company applied for a Mexican gaming license… The Las Vegas-based company recently made its foray into the B2C market, acquiring 80% of U.K.-based R Kings Competitions Ltd., one of Ireland’s and England’s leading independent online competition companies, with an option for the remaining 20%… As GMGI CEO Brain Goodman told Zingernation in a January interview, the economics of R Kings B2C model are ideal for scaling. The company spends less than a pound to acquire a player and generates north of 20 pounds from each one… Goodman added that his company is on the hunt for additional positive cashflow companies that could be immediately accretive and complementary to its core technologies.”

To view the full article, visit https://ibn.fm/BH0uf

About Golden Matrix Group Inc.

Golden Matrix, based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds configurable and scalable white-label social gaming platforms for its international customers, located primarily in the Asia Pacific region. The gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company’s platform can be accessed through both desktop and mobile applications. The company, through its 80% owned subsidiary, also runs a pay-to-enter prize competition in the United Kingdom and Ireland. Golden Matrix’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with current U.S. law. For more information, visit the company’s website at www.GoldenMatrix.com.

NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Why Aditxt Inc. (NASDAQ: ADTX) Is ‘One to Watch’

May 27, 2022 14:08:24

Aditxt (NASDAQ: ADTX) is a biotech company commercializing new innovations. The company’s first commercial product, AditxtScore(TM), is an immune mapping technology designed to provide a personalized, comprehensive profile of an individual’s immune system. “The company’s first commercial application of the platform, AditxtScore(TM) for COVID-19, delivers timely reports on vulnerability and immune status relating to SARS-CoV-2 and its known variants, giving consumers and physicians the data needed to make informed health decisions. Potential future applications will offer detection of an array of conditions, including diabetes, cardio-metabolic maladies and hormonal imbalances,” a recent article reads. Aditxt’s second innovation is a preclinical immune reprogramming technology, Apoptotic DNA Immunotherapy(TM) (“ADi(TM)”), which aims to retrain the immune system to induce tolerance and address disease-causing immune responses while maintaining the ability to combat pathogenic infections. Aditxt is currently developing ADi(TM) products for psoriasis, type 1 diabetes and skin grafting.

To view the full article, visit https://ibn.fm/INj2A

About Aditxt Inc.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Lexaria Bioscience (NASDAQ: LEXX) Leveraging Growing Commercial Opportunities

May 27, 2022 14:08:04

Lexaria is a biotechnology company focused on licensing its proprietary DehydraTECH(TM) technology
The DehydraTECH technology has been proven to increase the bioavailability, speed of onset and brain absorption of APIs, and improve customer experiences by masking unwanted tastes
Lexaria has 25 patents granted worldwide and is pursuing numerous other pending patent applications
The company operates several subsidiary companies to focus on different commercial opportunities

Ever since acquiring its first intellectual property (“IP”) that subsequently formed the basis of its first two patent application filings in 2014, biotechnology company Lexaria Bioscience (NASDAQ: LEXX) has grown the number of patents granted and patent applications exponentially, with 25 patents granted worldwide as of April 2022. The latest patent, the 10th granted in the United States, represents the first-ever patent for the use of DehydraTECH(TM) drug delivery technology in the enhanced delivery of antiviral drugs. Described by CEO Chris Bunka as “another validation of the versatility of our DehydraTECH drug technology,” the award of the IP protection marks a key step toward the ultimate monetization of DehydraTECH, according to an April 21 news release (https://cnw.fm/q8zmr).

This monetization, Lexaria’s annual report (Form 10-K filing) for the fiscal year ended August 2021 notes (https://cnw.fm/bCzFD), will be realized through the company’s focus on R&D and subsequent strategic…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]

CBDWire is part of the InvestorBrandNetwork.

Golden Matrix (NASDAQ: GMGI) Upgrades RKings Contest Platform

May 27, 2022 14:07:43

In December, Golden Matrix Group entered the B2C gaming market with the acquisition of the majority of U.K.-based skilled gaming company RKingsCompetitions Ltd.
This month, GMGI launched an upgraded version of the platform, which gives contestants the opportunity to win cars, electronics, tools, and more
The combination of GMGI’s B2B operations and new mix of B2C is lending to a surge in revenue and profits, reaching $8.9 million and $349,379, respectively in Q1. Q2 represents first full quarter of RKings in the financials

Gaming developer and licensor Golden Matrix Group (NASDAQ: GMGI) is a well-known and respected business-to-business (“B2B”) brand throughout the Asia Pacific region, delivering high-end white label online gaming solutions to operators. In December, the Las Vegas-based company made its foray into the business-to-consumer (“B2C”) marketplace, giving it greater exposure to a global gaming market that Naavik with BITKRAFT Ventures estimate at $336 billion.

The entrance into B2C was made through Golden Matrix acquiring an 80% stake in RKingsCompetitions Ltd., a United Kingdom-based company and leading operator of online skill-based competitions throughout the…

NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Energy Fuels (NYSE American: UUUU) (TSX: EFR) Elects Directors at Annual Meeting

May 27, 2022 14:07:21

Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading uranium producer in the United States, held the election of directors at its annual meeting of shareholders. The meeting was held virtually on May 25, 2022. During the meeting, the 10 nominees that were proposed for election by management were successfully elected. Elections were held via both proxy and electronic poll. The newly elected directors are J. Birks Bovaird, Mark S. Chalmers, Behamin Eshleman III, Ivy V. Estabrooke, Barbara A. Filas, Bruce D. Hansen, Jaqueline Herrera, Dennis L. Higgs, Robert W. Kirkwood and Alexander Morrison. All directors were elected by at least 84% of the vote. Energy Fuels supplies U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects as market conditions warrant and is ramping up to commercial production of rare earth element (“REE”) carbonate.

To view the full press release, visit https://ibn.fm/VCy1N

About Energy Fuels Inc.

Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. Energy Fuels also produces vanadium from certain of its projects as market conditions warrant and is ramping up to commercial production of rare earth element (“REE”) carbonate. With corporate offices in Lakewood, Colorado, and all of its assets and employees in the United States, Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today and has a licensed capacity of more than 8 million pounds of U3O8per year, has the ability to recycle alternate feed materials from third parties, to produce vanadium when market conditions warrant and to produce REE carbonate from various uranium-bearing ores. Energy Fuels is also evaluating the potential to recover medical isotopes for use in targeted alpha therapy cancer treatments. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U308 per year. In addition to the above production facilities, Energy Fuels also has one of the largest S-K 1300- and NI 43-101-compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
[email protected]

MiningNewsWire is part of the InvestorBrandNetwork.

GreenBox (NASDAQ: GBOX) Leveraging Acquisitions to Amplify Margin Profile

May 27, 2022 14:06:59

GreenBox (NASDAQ: GBOX), an innovative blockchain ledger fintech company, views acquisitions as a vital part of its growth strategy. Chairman Ben Errez notes that acquisitions allow the company to “Purchase merchant portfolios, adding processing volume to our platform, and provide a way to obtain key licensing assets, both domestically and globally, that enable us to branch out and service more verticals and geographic locations.” According to a recent article, GreenBox closed an asset purchase agreement with Sky Financial & Intelligence to acquire a portfolio of merchant accounts that contributed over $1 billion to the company’s total processing volume of about $2 billion for the full year 2021. “The acquisition of the substantial Sky portfolios is yet another stride forward for us and accomplishes two very important things,” commented Errez. “[First,] by bringing a large merchant account portfolio in-house, we eliminate the cost previously incurred from commissions and amplify our margin profile. Second, it allows GreenBox to own these customer relationships, securing a considerable portion of our processing volume base with the bonus of being able to offer additional revenue-generating solutions.”

To view the full article, visit https://ccw.fm/TYWRL

About GreenBox POS

GreenBox is an emerging financial technology company leveraging proprietary blockchain security to build customized payment solutions. The company’s applications enable an end-to-end suite of turnkey financial products, fraud detection and improving the efficiency of handling large-scale commercial processing volumes for its merchant clients globally. For more information, please visit the company’s website at www.GreenBoxPOS.com.

NOTE TO INVESTORS: The latest news and updates relating to GBOX are available in the company’s newsroom at https://ccw.fm/GBOX

About CryptoCurrencyWire (“CCW”)

To receive instant SMS alerts, text “CRYPTO” to 844-397-5787 (U.S. Mobile Phones Only)

CryptoCurrency News Wire is where News, content and information converge via Crypto.

For more information, please visit https://www.CryptoCurrencyWire.com

Please see full terms of use and disclaimers on the CryptoCurrencyWire (CCW) website applicable to all content provided by CCW, wherever published or re-published: http://CCW.fm/Disclaimer

CryptoCurrencyWire (CCW)
New York, New York
www.CryptoCurrencyWire.com
212.994.9818 Office
[email protected]

CryptoCurrencyWire is part of the InvestorBrandNetwork

Cybin (NEO: CYBN) (NYSE American: CYBN) Boosted by New Study of Psychedelic Compounds

May 27, 2022 14:06:38

Recent study indicates psychedelic compounds show significant promise in treating a range of mental-health disorders
Participants given psilocybin therapy reported a rapid, sustained improvement in their depression
Cybin’s CYB003 has demonstrated less variability, faster onset, shorter duration and better brain penetration than oral psilocybin

A new study sponsored by Imperial College London reports that psychedelic compounds may be effective in treating mental-health disorders (https://ibn.fm/xSdZv). The study supports efforts made by Cybin (NEO: CYBN) (NYSE American: CYBN), which is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental-health disorders.

“Psychedelic compounds like LSD, Ecstasy and psilocybin mushrooms have shown significant promise in treating a range of mental-health disorders, with participants in clinical studies often describing tremendous progress taming the demons of…

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Knightscope (NASDAQ: KSCP) Featured in The Alden Report Interview

May 25, 2022

May 25, 2022 14:27:32

Knightscope’s (NASDAQ: KSCP) Chairman and CEO, William Santana Li, was featured on a recent episode of The Alden Report, a podcast series aimed at supporting wellness and self-improvement. During the interview, Li discussed Knightscope and the significant societal need it is addressing with its autonomous security robots.

“There are a million security guards and a million law enforcement professionals… You typically need four people to cover a 24/7 post, so, at any given time, there’s only 500,000 people trying to secure 328 million Americans across 50 states. That math doesn’t work,” Li said. “[Knightscope’s autonomous security robots] are designed to do a couple of things. One is to provide a physical deterrence… The second thing is that these machines generate over 90 terabytes of data a year… They can read several hundred license plates per minute, some of them have facial recognition, officers and guards can speak through the machines. It’s having eyes, ears and voice on the ground – in multiple locations at the same time. It’s almost like giving officers and guards superhuman capabilities at their fingertips.”

Knightscope also announced the schedule for its Annual Meeting of Stockholders. The “Annual Meeting” will be held entirely online, beginning at 9:00 a.m. Pacific Time on Thursday, June 23, 2022.

The announcement reads, “In addition to typical annual business matters, Knightscope Chairman and CEO, William Santana Li, will provide important updates and will share at least one special announcement. Stockholders will be able to attend and participate in the Annual Meeting at www.meetnow.global/MCPTMNT and vote… The Notice of Annual Meeting of Stockholders, our Proxy Statement, and our 2021 annual report are available at www.envisionreports.com/KSCP. Stockholder participation in the affairs of the company is important. Those unable to attend the meeting are encouraged to review the proxy materials above and vote ahead of the Annual Meeting online or by phone.”

To view the full press releases, visit https://ibn.fm/T9MhU and https://ibn.fm/hVR82

About Knightscope

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Lexaria Bioscience (NASDAQ: LEXX) Making Waves in the Antiviral Drug Space

May 25, 2022

May 25, 2022 14:27:12

Lexaria Bioscience Corp., through its patented DehydraTECH technology, is improving the way many drugs enter the bloodstream
In June 2021, the company proved that an antiviral drug enhanced with its technology was effective at inhibiting the COVID-19/SARS-CoV-2 virus
With the global antiviral market projected to hit $66.7 billion by 2025, Lexaria plans to capitalize on this growth by pushing its DehydraTECH technology and exploring multiple avenues of related application

Today, it is estimated that infectious diseases account for a quarter to one-third of mortality globally. This has mainly been attributed to increased travel, globalization, populated cities, urbanization, and changes in human behavior, among other reasons. These mortalities occur despite significant advancements and developments in the pharmaceutical industry, as has been well evidenced by recent virus outbreaks, including Covid-19, SARS, and Swine Flu, among others (https://cnw.fm/gis8Y).

The current concerns surrounding virus-related and other diseases encourage the medical industry to revisit its approach to treating such conditions. A viable solution that has been identified is the…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Flora Growth (NASDAQ: FLGC) Increases Vessel’s Footprint in the Canadian Cannabis Market

May 25, 2022

May 25, 2022 14:26:48

Flora Growth’s Vessel brand just got listed on the Ontario Cannabis Store (“OCS”)
Vessel also launched its direct-to-consumer online store to take control of its customer relationship journey
Flora, through this expansion, seeks to tap into the growing Canadian cannabis market, which is valued at an estimated CAD 5.9 billion in 2022
The company has also expanded its operational footprint in Europe and the U.K. in a move that furthers its international growth strategy

Flora Growth (NASDAQ: FLGC) just announced that its Vessel brand just got listed on the Ontario Cannabis Store (“OCS”) in a move that significantly increases the brand’s footprint in the Canadian cannabis marketplace. In addition, Vessel also announced the launch of its Canadian direct-to-consumer online store, www.VesselBrand.ca, to allow the brand to take control of its customer relationship and journey (https://cnw.fm/WWjdA).

Vessel brand is a leader in the premium cannabis accessories market, having been acquired by Flora Growth back in November 2021. Known for its go-to-market strategy for direct-to-consumer sales in the United States and international cannabis markets, this brand has…

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

SRAX (NASDAQ: SRAX) Shares Presentations, Keynotes from Sequire Fintech Conference

May 24, 2022 13:43:54

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (“SaaS”) platform, is making replays from its 2022 Sequire Fintech Conference presentation available. SRAX hosted the virtual investor event on May 19, 2022. During the conference, premier fintech stock market companies made key presentations to investor attendees; industry experts also provided keynote addresses during the event. The event was sponsored by Apex Fintech Solutions, Banxa Holdings Inc., Usio Inc. and Newtek Business Services Corp. According to the announcement, those interested can view the keynote address, panel discussions and company presentations free of charge.

To view the presentation and keynote replays, visit https://ibn.fm/xcD0C

To view the full press release, visit https://ibn.fm/wPepA

About SRAX Inc.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Cybin (NYSE American: CYBN) (NEO: CYBN) Partners to Accelerate Pathway of CYB003

May 24, 2022 13:43:21

Cybin (NYSE American: CYBN) (NEO: CYBN) is moving forward with its phase 1/2a clinical trial of its proprietary deuterated psilocybin, CYB003, which, previous research shows, has the potential to effectively treat major depressive disorder (“MDD”) with significant advantages over classic psilocybin. MDD impacts over 264 million people worldwide, 1/3 to 1/2 of whom demonstrate an inadequate response to antidepressant drug treatment. Against this backdrop, Cybin focuses on finding solutions for those whose lives are impacted by MDD and other mental and emotional disorders. “The company recently completed in vivo preclinical studies of CYB003. The company plans to file an investigational new drug application with the U.S. Food and Drug Administration for its upcoming phase 1/2a clinical trial. Cybin anticipates initiating the trial mid-year,” a recent article reads. “Cybin announced that it has selected Clinilabs Drug Development Corporation to support the clinical trial. Clinilabs is a global, full-service contract research organization with an impressive reputation for its expertise in central nervous system drug development. Cybin CEO Doug Drysdale said, ‘Clinilabs is ideally suited to help us accelerate the regulatory pathway for this promising treatment candidate and, ultimately, to treat those suffering from MDD effectively.’”

To view the full article, visit https://ibn.fm/eOB6k

About Cybin Inc.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Nicotine Surges as Smoking Sags

May 24, 2022 13:42:49

NetworkNewsWire Editorial Coverage: Seems like yesterday people were smoking cigarettes everywhere; many people still have memories of Grandpa puffing on his Camels. It wasn’t until 1993 that smoking was banned in hospitals and on airplanes in 1998. Despite these and many other restrictions, the global market for nicotine-based products remains incredibly robust. Total global retail sales associated with the nicotine ecosystem during 2020 reached approximately $853 billion with around 5.2 trillion retail cigarette sticks sold. Nicotine isn’t just big business, it’s huge business, and companies are constantly looking for ways to keep and grow market share.

The majors are evermore turning to innovation and alternative delivery methods to achieve their objectives. An example of that is the breakthrough technology of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile) and its patented DehydraTECH(TM) delivery platform. Suitable for use across a wide range of product formats such as pharmaceuticals, nutraceuticals and over-the-counter products, Lexaria’s DehydraTECH also increases the delivery characteristics of orally administered nicotine.

Multiple companies have already licensed DehydraTECH technology and are paying royalties to Lexaria for its use. Lexaria has licensed DehydraTECH to the Altria Group (NYSE: MO), the largest tobacco company in the country, which is currently evaluating the tech for possible use in noncombusted oral nicotine products. In addition, British American Tobacco Industries p.l.c. ADR (NYSE: BTI) has conducted some early evaluation of Lexaria’s tech, and the market is waiting to hear if either company might implement it. Meanwhile, Philip Morris International (NYSE: PM) is aggressively pursuing tobacco-free nicotine products as GlaxoSmithKline PLC (NYSE: GSK) tries to wean folks from nicotine…

CNS Pharmaceuticals (NASDAQ: CNSP) to Present at H.C. Wainwright Conference

May 24, 2022 13:42:31

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its CEO John Climaco will be participating at the H.C. Wainwright Global Investment Conference. The event is slated to take place May 23-26, 2022, virtually and in-person in Miami, Florida. A video webcast of Climaco’s presentation is now accessible for viewing on-demand for registered attendees and will be available on the company’s website. Following the event, the webcast replay will be archived for 90 days. In addition, CNSP management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

To view the full press release, visit https://ibn.fm/KhJSJ

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Watch for Continued Gains in Shares of ConocoPhillips (COP)

May 23, 2022 12:02:41

ConocoPhillips (NYSE:COP) traded today at a new 12-month high of $108.67. This new high was reached on below average trading volume as 2.7 million shares traded hands, while the average 30-day volume is approximately 7.4 million shares.

In the past 12 months, ConocoPhillips share prices are bracketed by a low of $51.41 and a high of $108.67 and are now at $108.23, 111% above that low price.

ConocoPhillips is a U.S.-based independent exploration and production firm. At the end of 2020, it produced 727,000 barrels per day of oil and natural gas liquids and 2.4 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2020 were 4.5 billion barrels of oil equivalent.

ConocoPhillips is currently priced 39.5% above its average consensus analyst price target of $65.45.

About BillionDollarClub

BillionDollarClub (BDC) is the exclusive home of the biggest and brightest companies covered by IBN, a financial news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution to nearly 2 million followers, and (5) a full array of corporate communications solutions. This is the place you want to be, where every covered company has a market cap in excess of $1 billion. By cutting through the overload of information in today’s market, BDC brings its clients unparalleled visibility, recognition and brand awareness. While IBN’s client list includes companies big and small, BillionDollarClub is the gold standard.

To receive SMS text alerts from BillionDollarClub, text “Billion” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BillionDollarClub.com

Please see full terms of use and disclaimers on the BillionDollarClub website applicable to all content provided by BDC, wherever published or re-published: http://IBN.fm/Disclaimer

BillionDollarClub (BDC)
Los Angeles, California
www.BillionDollarClub.com
310.299.1717 Office
[email protected]

BillionDollarClub is part of the InvestorBrandNetwork.

Sociedad Quimica y Minera S.A. (SQM) Climbs to Annual-High Share Price

May 23, 2022 12:02:21

Sociedad Quimica y Minera S.A. (NYSE:SQM) traded at a new 12-month high today of $99.15. So far today approximately 723,000 shares have been exchanged, as compared to an average 30-day volume of 1.9 million shares.

Sociedad Quimica y Minera S.A. is currently priced 2.8% above its average consensus analyst price target of $95.22.

Sociedad Quimica y Minera de Chile is a Chilean commodities producer with significant operations in lithium ( primarily used in batteries for electric vehicles and energy storage systems), specialty and standard potassium fertilizers, iodine ( primarily used in X-ray contrast media), and solar salts. The company extracts these materials through its high-quality caliche ore and salt brine deposits. SQM is also developing a hard rock lithium project in Australia.

In the past 12 months, shares of Sociedad Quimica y Minera S.A. have traded between a low of $40.53 and a high of $99.15 and are now at $97.98, which is 142% above that low price.

About BillionDollarClub

To receive SMS text alerts from BillionDollarClub, text “Billion” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BillionDollarClub.com

Please see full terms of use and disclaimers on the BillionDollarClub website applicable to all content provided by BDC, wherever published or re-published: http://IBN.fm/Disclaimer

BillionDollarClub (BDC)
Los Angeles, California
www.BillionDollarClub.com
310.299.1717 Office
[email protected]

BillionDollarClub is part of the InvestorBrandNetwork.

Mullen Automotive (NASDAQ: MULN) Names New President of International Operations

May 23, 2022 10:39:37

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has announced a new president of international operations: Richard Curtis. Previously president of the Imperium Motor Company, Curtis has served as a turnaround specialist for Lithia Automotive group in three western states. In addition, he was director of electric vehicles for the largest privately owned dealer group in Northern California. Under his leadership, the group earned the distinction of being the top-volume EV seller for the Nissan Leaf, Fiat 500 EV and Chevrolet Volt. “Richard has tremendous experience throughout Asia and will be key to expanding our presence there and beyond,” said Mullen CEO and chair David Michery in the press release. “His 35 years plus of automotive experience, working with large dealer groups and international OEMs, brings a level of global expertise that will be a central factor in growing our EV business around the world.”

To view the full press release, visit https://ibn.fm/6Pm5G

About Mullen Automotive Inc.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Nemaura Medical (NASDAQ: NMRD) Secures $5M in Non-Dilutive Funding

May 23, 2022 10:39:14

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on commercializing a daily disposable wearable glucose sensor and supporting personalized digital coaching programs. The company today announced that it has secured $5 million in non-dilutive funding though a clean debt facility with no warrants or convertible elements. Under the current financing, existing debt repayments have been deferred for nine months. “Given the current market conditions, we believe that a loan of this type with no additional dilutive terms is a testament to Nemaura’s future potential,” the company’s CEO Faz Chowdhury said in the news release. “Equally as important, it ensures we have ample cash to execute on our ambitious plans.”

To view the full press release, visit https://ibn.fm/12wOB

About Nemaura Medical Inc.

Nemaura is a medical technology company developing and commercializing wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a Premarket Approval Application (“PMA”) for sugarBEAT to the U.S. FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital health care subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT(R) diabetes program that is currently undergoing pilot studies. Additionally, Nemaura has launched Miboko, a new metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being. The company sits at the intersection of the global type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information, please visit www.NemauraMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Flora Growth (NASDAQ: FLGC) Announces Acquisition of Masaya CB Brand

May 23, 2022 10:38:54

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, has signed an agreement to acquire Masaya and its patent-pending CBD formulations, including Masaya Pure. The agreement was made with leading cell biologist Dr. Annabelle Manalo-Morgan, PhD, who created and owns the brand; Manalo-Morgan is a member of Flora Growth’s board of directors and is the company’s scientific advisor. According to the announcement, Masaya’s exclusive CBD oil formulations contain no THC and have garnered numerous testimonials. The brand will be the first offering from Flora Life Sciences in the United States, and the company anticipates distributing the brand globally. FLGC has already started the process of registering the proprietary formulation with INVIMA, Columbia’s regulatory agency. The company will also be including the Masaya Pure formulation in current clinical trials being conducted in collaboration with the University of Manchester in the United Kingdom. “We are excited to announce the acquisition of Masaya,” said Flora Growth CEO and chair Luis Merchan in the press release. “The brand’s formulation was developed by Dr. Annabelle for her son and has since been used by thousands of consumers. Amplifying Dr. Annabelle and her son’s beautiful story and improving the well-being of people around the world is our aim. This acquisition allows us to deliver on our promise to invest in safe, thorough, cutting-edge scientific research that can bring meaningful change via an efficacious and accessible product offering for people worldwide.”

To view the full press release, visit https://cnw.fm/IYhQ7

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands designed to deliver the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to commercial, house of brands, and life sciences divisions. For more information about the company, please visit www.FloraGrowth.ca.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria (NASDAQ: LEXX) Aims to Deliver Safer Alternative for Nicotine Experience

May 20, 2022

May 20, 2022 10:13:54

Lexaria Bioscience Corp. (NASDAQ: LEXX) will soon begin a human clinical study, NIC-H22-1, to compare its DehydraTECH-nicotine pouch performance with that of existing brands such as ON! and Zyn, currently available in the U.S. “Animal testing has already demonstrated that DehydraTECH-nicotine can deliver peak nicotine performance to the bloodstream 10 to 20 times faster than the study’s controls,” a recent article reads. “Lexaria has long held that any form of inhaling chemical substances can be detrimental to health, and its DehydraTECH-nicotine aims to help vapers as well as smokers wean themselves off of those products, giving them relief from cravings while offering a safer nicotine alternative. ‘My father also died from lung cancer … so I am no fan [of smoking],’ CEO Chris Bunka told Forbes in 2019. ‘The fact that [DehydraTECH] is fast means that smokers might not be frustrated waiting for their nicotine experience to begin, the way they have been with traditional nicotine products such as gums and lozenges.’”

To view the full article, visit https://cnw.fm/UO4Jl

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Nemaura Medical (NASDAQ: NMRD) to Participate in H.C. Wainwright Conference

May 20, 2022

May 20, 2022 10:13:29

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, and its CEO Dr. Faz Chowdhury will be attending the upcoming H.C. Wainwright Global Hybrid Investment Conference. The conference is slated for May 23–26, 2022, in Miami Beach, Florida. Chowdhury has been invited to present during the event; his virtual presentation is slated for May 24, and will be available on demand beginning 7 a.m. ET. According to the company, Chowdhury’s presentation will include updates on recent business developments. Chowdhury will also be available for one-on-one meetings with investors.

To view the full press release, visit https://ibn.fm/mMNlH

About Nemaura Medical Inc.

Nemaura Medical is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R)and proBEAT(TM). sugarBEAT, a CE mark-approved class IIb medical device, is a noninvasive and flexible continuous glucose monitor (“CGM”) that provides actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a premarket approval application (“PMA”) for sugarBEAT to the U.S. Food and Drug Administration (“FDA”). proBEAT combines noninvasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the United States as a general wellness product as part of NMRD’s BEAT diabetes program. Additionally, Nemaura has launched Miboko, a new metabolic health and well-being program using a noninvasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being. Nemaura sits at the intersection of the global type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50-plus billion prediabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information about the company, visit www.NemauraMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Energy Fuels (NYSE American: UUUU) (TSX: EFR) Enters Agreement for Rare Earth Land Position

May 20, 2022

May 20, 2022 10:13:03

Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading uranium producer in the United States, has signed binding agreements to secure an estimated 58.3 square-mile, heavy-mineral sand position. The agreements cover the acquisition of 17 mineral concessions located between Prado and Caravelas, towns in the state of Bahia, Brazil. Called the Bahia Project, the area has potential to feed the Energy Fuel’s White Mesa Mill with rare earth element and uranium bearing natural monazite sand for decades. “This is another very significant step in Energy Fuels’ development as a major global rare earth element producer based in the United States,” said Energy Fuels president and CEO Mark S. Chalmers. “We are aggressively seeking to expand our monazite sand feeds. With guidance from our heavy-mineral sand experts, the company has been evaluating the acquisition of monazite-bearing projects. The Bahia deposit is well-known throughout the HMS industry as having excellent potential to produce high-quality ilmenite, rutile and zircon products, in addition to monazite. We are very pleased to have secured this project, as it has the potential to provide Energy Fuels with our own low-cost source of monazite feed that we fully control. The company expects to supplement its monazite supply in the future with open market purchases, arrangements with existing monazite producers, and/or additional acquisitions. Energy Fuels is in advanced discussions with other current and future monazite producers around the world to provide creative options on how to best build upon our momentum and add further scale.”

To view the full press release, visit https://ibn.fm/Kdp1Q

About Energy Fuels Inc.

Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8to major nuclear utilities. Energy Fuels also produces vanadium from certain of its projects, as market conditions warrant, and is ramping up commercial-scale production of REE carbonate. Its corporate offices are in Lakewood, Colorado, near Denver, and all its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) project in Wyoming, and the Alta Mesa ISR project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of more than 8 million pounds of U3O8per year and has the ability to produce vanadium when market conditions warrant as well as REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR project is on standby and has a licensed capacity of 2 million pounds of U3O8per year. The Alta Mesa ISR project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8per year. In addition to the above production facilities, Energy Fuels has one of the largest NI 43-101 compliant uranium resource portfolios in the country, along with several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About MiningNewsWire

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
[email protected]

MiningNewsWire is part of the InvestorBrandNetwork.

Golden Matrix Group (NASDAQ: GMGI) Seeks to Cement Position in Online Gaming Industry

May 19, 2022 11:45:41

Golden Matrix Group have emerged as one of the online gaming industry’s most extensive gaming portfolio providers
The company provides gaming platforms with access to over 10,000 games drawn from upwards of 25 gaming studios
Golden Matrix have sought to further cement their position within the gaming industry through the recent launch of their next generation B2B GMX-Ag system
Simultaneously, the company has looked to bolster its gaming portfolio, most recently through a tie-up with Spearhead Studios, which will see the later companies over 90 proprietary video games added to GMGI’s extensive product offering

According to games directory SlotCatalog, there are currently over 23,000 online casino games available today, produced by over 450 gaming studios. Tens of studios emerge each year, only to find success largely fleeting due to a limited product portfolio or name recognition. Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems, and gaming content have sought to bridge the gap between gaming operators and studios through the launch of its B2B aggregate gaming system, GMX-Ag.

Golden Matrix’s GM-X system has long been established as the industry standard, granting gaming platforms with access to upwards of 10,000 games from a broad array of over 25 gaming studios via a singly gaming API – firmly cementing its position as the industry’s most extensive gaming portfolio…

NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

About InvestorWire

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Flora Growth (NASDAQ: FLGC) Revolutionizing the Plant-Based Wellness and Lifestyle Industry

May 19, 2022 11:45:09

Flora Growth has been building a design-led collective of plant-based wellness and lifestyle brands
Through the work done by its pharma division, the company earned over $31.5 million in gross proceeds in the year ended November 2021
The company still maintains its revenue guidance projection of $35-45 million for 2022, attributed mainly to product diversification initiatives, strengthening its supply chain, and adoption of cost-effective cultivation practices

Since its inception, Flora Growth (NASDAQ: FLGC) has remained committed to building a design-led collective of plant-based wellness and lifestyle brands. This objective has defined Flora Growth’s three central pillars- wholesale cannabis, pharmaceutical cannabis, and CPG cannabis brands. Moreover, it has given the company and its management a platform to interact with and exchange ideas with other players in the plant-based wellness space, even as it seeks to grow its revenue through acquisitions and strengthening its distribution network.

Specifically, Flora Growth’s pharma division has been a leader in its sector. Headed by Dr. Annabelle Morgan-Manalo, a renowned neuroscientist, this division aims to understand the applicable modalities and formulations of cannabinoid-based products that…

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

CNS Pharmaceuticals (NASDAQ: CNSP) to Present at American Society of Clinical Oncology Meeting

May 19, 2022 11:44:35

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced acceptance of its abstract for poster presentation at the American Society of Clinical Oncology (“ASCO”) 2022 Annual Meeting. Being held virtually and in Chicago, Illinois, the event is slated to take place from June 3-7, 2022. The abstract is titled “Design and initiation of an adaptive, randomized, controlled study of berubicin, a topoisomerase 2 poison that crosses the blood brain barrier (‘BBB’), for the treatment of recurrent glioblastoma multiforme (‘GBM’) after first-line therapy.” Sandra L. Silberman, M.D., Ph.D., chief medical officer of CNS Pharmaceuticals, is the presenter in the “Poster Session/Central Nervous System Tumors” scheduled from 8 a.m. to 11 a.m. CT on Sunday, June 5, 2022.

To view the full press release, visit https://ibn.fm/sdfI7

About CNS Pharmaceuticals Inc.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

As Nation Grapples with Violent Crime, Knightscope (NASDAQ: KSCP) Expands Influence

May 19, 2022 11:43:40

Violent crime in the United States grew at a record percentage rate during 2020
The autonomous security robots developed by Silicon Valley-based Knightscope are designed to help deter criminal activity by helping bad actors to recognize that their misbehavior may be observed and recorded to be used against them
Knightscope has been in operation for over 1.5 million hours and has produced three robotic models adaptable to a variety of client facility needs
The company has recorded a number of crime-intervention successes, and recently reported its first contract with a Las Vegas casino property to help protect the business’s guests

A historic drought in the western United States has revived interest in the “Godfather” era of the Mafia, after water levels in the power-supplying Lake Mead reservoir east of Las Vegas fell sharply to a point that a couple of long-submerged bodies were exposed — one of them in a rusted barrel.

“There’s no telling what we’ll find in Lake Mead,” former Las Vegas Mayor Oscar Goodman told media outlets (https://ibn.fm/Bv7nx). “It’s not a bad place to dump a…

NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

About InvestorWire

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

GreenBox (NASDAQ: GBOX) to Present at H.C. Wainwright Global Investment Conference

May 19, 2022 11:42:17

GreenBox (NASDAQ: GBOX), an emerging and rapidly growing fintech company, today announced its participation in the H.C. Wainwright Global Investment Conference. The event is slated to take place in a virtual and in-person format at the Fontainebleau Miami Beach Hotel on May 23-26, 2022. GreenBox Chairman Ben Errez will give a company presentation and will be available for virtual one-on-one meetings with investors. Errez’s presentation is scheduled to begin at 7 a.m. ET on Tuesday, May 24, and will be available on demand. Interested parties should visit https://ccw.fm/7iSHF to register and view the webcast.

To view the full press release, visit https://ccw.fm/g0847

About GreenBox POS

NOTE TO INVESTORS: The latest news and updates relating to GBOX are available in the company’s newsroom at https://ccw.fm/GBOX

About CryptoCurrencyWire (“CCW”)

To receive instant SMS alerts, text “CRYPTO” to 844-397-5787 (U.S. Mobile Phones Only)

CryptoCurrency News Wire is where News, content and information converge via Crypto.

For more information, please visit https://www.CryptoCurrencyWire.com

Please see full terms of use and disclaimers on the CryptoCurrencyWire (CCW) website applicable to all content provided by CCW, wherever published or re-published: http://CCW.fm/Disclaimer

CryptoCurrencyWire (CCW)
New York, New York
www.CryptoCurrencyWire.com
212.994.9818 Office
[email protected]

CryptoCurrencyWire is part of the InvestorBrandNetwork

Nemaura Medical’s (NASDAQ: NMRD) UK Licensee Begins Direct-to-Consumer Campaign

May 18, 2022 09:48:56

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced that MySugarWatch, its UK licensee is launching a direct-to-consumer campaign in “Daily Mail,” one of the United Kingdom’s largest daily newspaper. The campaign is part of MySugarWatch’s large-scale awareness efforts focused on NMRD sugarBEAT noninvasive continuous glucose monitor. The campaign is designed to reach the newspaper’s 1.2 million-plus daily readers and involves ads that are part of the company’s wider efforts, which targets both consumers and professionals. “Embarking on the consumer phase of our UK licensee’s campaign in support of the commercialization efforts around sugarBEAT is very exciting, and we are looking forward to continuing our support for our licensee,” said Nemaura CEO Faz Chowdhury, PhD, in the press release. “Our commitment to supporting MySugarWatch’s success remains strong, and we look forward to the opportunity to provide what is potentially a game-changing non-invasive CGM, to potential users in the UK.”

To view the full press release, visit https://ibn.fm/1zgkL

About Nemaura Medical Inc.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

GreenBox POS (NASDAQ: GBOX) Releases Q1 2022 Financial Report, Corporate Update

May 18, 2022 09:48:10

GreenBox (NASDAQ: GBOX), an emerging and rapidly growing fintech company, is reporting its financial numbers for the first quarter ending March 31, 2022. Highlights of the report include Q1 revenues of $4.9 million, up from $4.7 million in the same quarter last year and a processing volume growth for the quarter of $754 million versus $315 million last year. In addition, the company noted that it completed two acquisitions, including its largest acquisition to date, expanding the company’s global footprint with the acquisition of Transact Europe, and that it closed a significant licensing partnership with Cross River Bank, designed to launch banking as a service offering and expand the universe of new customers while creating incremental channels for revenue growth. Additions were made to the board of directors and executive management team and the company accelerated its share repurchase program and announced INNOCEAN as its global marketing agency.

In addition, GreenBox chair Ben Errez was featured in the most recent Bell2Bell podcast. The podcast delivers updates and exclusive interviews with executives operating in fast-moving industries. Throughout the interview, Errez and host Stuart Smith talked about the history of the company as well as its business model, operating markets and objectives. “I divide the goals for the company into several parallels,” said GreenBox chair Ben Errez in the interview. “Number one is geographic control and expansion. Most of our business today is done within the U.S., but with our completed acquisition in Europe that we announced recently, you can tell that our global expansion will begin in that region. . . . The second slice is the type of business that we do. . . . Obviously, the company makes a lot more money in the form of transactional fees when we do transactions in the mid- to high-risk space; however, we can’t do just that. We have to have a blend that fits the risk profile of the company in general. . . . Overall, we’re looking at 60% low-risk, 40% medium-to-high-risk. That’s the general goal.”

To view the full interview, visit https://ccw.fm/5vG6K

To view the full press releases, visit https://ccw.fm/RwiGc and https://ccw.fm/aDBKE

About GreenBox POS

GreenBox is an emerging financial technology company leveraging proprietary blockchain security and token technology to build customized payment solutions. The company’s applications enable an end-to-end suite of turnkey financial products, fraud detection and improving the efficiency of handling large-scale commercial processing volumes for its merchant clients. For more information about the company, please visit www.GreenBoxPOS.com.

NOTE TO INVESTORS: The latest news and updates relating to GBOX are available in the company’s newsroom at https://ccw.fm/GBOX

About CryptoCurrencyWire (“CCW”)

To receive instant SMS alerts, text “CRYPTO” to 844-397-5787 (U.S. Mobile Phones Only)

CryptoCurrency News Wire is where News, content and information converge via Crypto.

For more information, please visit https://www.CryptoCurrencyWire.com

Please see full terms of use and disclaimers on the CryptoCurrencyWire (CCW) website applicable to all content provided by CCW, wherever published or re-published: http://CCW.fm/Disclaimer

CryptoCurrencyWire (CCW)
New York, New York
www.CryptoCurrencyWire.com
212.994.9818 Office
[email protected]

CryptoCurrencyWire is part of the InvestorBrandNetwork

Mullen Automotive (NASDAQ: MULN) Adds Key Personnel to Support Growth

May 18, 2022 09:47:46

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has released a list of new employees that have been carefully hired to fuel the company’s success and support the company’s growing EV offerings, including the Mullen FIVE EV Crossover and Mullen ONE EV Cargo Van. The individuals are filling roles in an array of areas, such as vehicle engineering, vehicle integration, powertrain systems and manufacturing, and are working in several different locations, including Mullen’s vehicle team in Anaheim, California; its powertrain team in Monrovia, California; and its AMEC manufacturing team in Tunica, Mississippi. The new hires include product engineers Robert Huotari, the company’s new director of Interiors; Mark Jenkins, a new design engineer; and Ameil Kapadia, senior manager over BIW Engineering. In manufacturing, the company hired Cesar Aguirre, manager BIW advanced manufacturing engineer; Amanda Hancock, HR manager; Allen McDonald, plant controller; Kyler Ohl, IT systems architect; John Roberts, facilities supervisor; Jesse Satterfield, manager, PC and L; Jack Saylor, production manager and tech specialist; and Michelle Saylor, global manufacturing assistant. Vedanth Basappa, a manager in Virtual Simulation, and Scott Newton, a packing engineer, joined Mullen’s vehicle integration team, and Albert Lizardo was hired as a senior manager in thermal systems. “I am happy to announce the addition of these new members to the Mullen Automotive Team,” said Mullen Automotive CEO and chair David Michery in the press release. “Every new team member is a vital hire and an integral part of our EV programs and bright future for Mullen Automotive. One of our promises from the start has been to put Americans back to work in the U.S., and I fully intend to see my commitment through.”

To view the full press release, visit https://ibn.fm/lVuRS

About Mullen Automotive Inc.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Cybin (NEO: CYBN) (NYSE American: CYBN) Participating in May 18 NYSE Bell Ceremony

May 18, 2022 09:47:16

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the morning trading bell ceremony at the New York Stock Exchange on May 18, 2022. The first psychedelics company to be listed on the NYSE, Cybin started trading on the exchange in August 2021. In addition, Cybin announced that management team members will be hosting in-person meetings with institutional investors in New York City on May 18–19. “We are delighted to be part of this ceremony as we celebrate the innovation that Cybin is bringing to the challenges of mental health treatments today,” said Cybin CEO Doug Drysdale in the press release. “As we progress from promising preclinical studies toward first-in-human trials, we are steadfastly committed to bringing improved therapeutic options to the millions of people who can benefit from our psychedelic-based therapies as quickly as possible.”

To view the full press release, visit https://ibn.fm/dWkRS

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Knightscope (NASDAQ: KSCP) to Deploy ASR Service for Fortune 500 Distribution Center

May 18, 2022 09:46:40

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, today announced that a Kentucky-based Fortune 500 distribution center is the latest client to subscribe to its Autonomous Security Robot (“ASR”) service.

The announcement reads, “Distribution, manufacturing and shipping warehouses have long been targets for criminals due to several unique characteristics presenting a range of security threats that can be challenging to solve. Such examples include their proximity to high-crime areas; the often-valuable property located on premises (many times attracting employees to steal); the use of potentially lethal hazards leading to false/fraudulent injury claims; high traffic and turnover making restricted access to controlled areas difficult; and property size inhibiting large scale safety patrols. A K5 ASR monitored remotely is able to address each of these concerns and will add an invaluable layer of security to this client’s safety protocols.”

To view the full press release, visit https://ibn.fm/KujDq

About Knightscope

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Golden Matrix Group (NASDAQ: GMGI) Launches Upgraded RKings Tournament Platform

May 18, 2022 09:46:16

Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of gaming platforms, systems and gaming content, has launched an upgraded Tournament platform. The robust new version of the platform includes added features and functionality specifically for Rkings’ players in Ireland and the United Kingdom. GMGI anticipates that the new platform will lead to an increase in the monthly number of skill tournaments as well as the number of participants, which should generate stronger revenue and profit from the RKings’ space. In addition, the company noted that the platform can be introduced into other regulated markets because of its scalability. GMGI is waiting for approval on its Mexican gaming permit, and then the company plans to take the platform live in that country. “This significant upgrade to the RKings platform will accelerate the growth of our B2C businesses, offering added functionality and features and also allowing us to expand into new geographic regions and strengthen our global footprint,” said Golden Matrix CEO Brian Goodman in the press release. “We believe the GMGI/RKing product offerings will be received enthusiastically by players in all regulated markets where we are licensed. At a time when global economic growth is being challenged, we are fortunate to have a scalable business model that has already demonstrated consistent profitability.”

To view the full press release, visit https://ibn.fm/RiiUq

About Golden Matrix Group Inc.

Golden Matrix Group, based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds configurable and scalable white-label B2B gaming platforms for its international customers, located primarily in the Asia-Pacific region. The company’s gaming IP includes tools for marketing, acquisition, retention and monetization of users. GMGI’s platform can be accessed through both desktop and mobile applications. As a result of its 80% controlling ownership interest in UK-based RKings Competitions Ltd., Golden Matrix also generates revenues from RKings’ scalable B2C tournament platform. For more information about the company, visit www.GoldenMatrix.com

NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Cepton (NASDAQ: CPTN) CEO to Present at TechCrunch’s Signature Annual Event

May 17, 2022 10:35:18

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance MMT(R) lidar solutions, today announced that its CEO Dr. Jun Pei will speak at TechCrunch’s signature annual event TC Sessions: Mobility 2022 in San Mateo, California, taking place on May 18-20, 2022. Cepton is scheduled to present at 11:45 a.m. PT on May 19. In the session titled “Breaking the luxury spell: A journey to commercializing safe autonomy for all,” Dr. Pei will address common misconceptions about liar technology and discuss how Cepton’s Micro Motion Technology (MMT(R)) enables scalable lidar solutions for everyday consumer vehicles. “The lidar industry is at an inflection point where we are truly confident in the pivotal role lidar plays in changing the future of mobility,” said Dr. Pei. “Last year, General Motors introduced Ultra Cruise as a solution that ultimately enables ‘door-to-door hands-free driving.’ This aligns with our vision to bring safe, autonomous transportation to everyone. While lidar is a key enabler of autonomous driving, we also believe that safety should be the standard for all levels of autonomy, and lidar is essential to the enhancement of automotive safety. With that, we are dedicated to commercializing lidar for everyday passenger cars. I look forward to sharing Cepton’s journey to the industry’s largest ADAS lidar series production award, and to discuss the work that has been done at Cepton to make safe autonomy accessible to all.”

To view the full press release, visit https://ibn.fm/bBtwz

About Cepton Inc.

Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented Micro Motion Technology (“MMT(R)”), Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability, while enabling scalable and intelligent 3D perception solutions across industries. Cepton has been awarded the largest known ADAS lidar series production award in the industry to date, based on the number of vehicle models awarded, to support General Motors’ Ultra Cruise program. Cepton is also engaged with all other Top 10 global OEMs. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to the OEM and Tier 1-studded Metro Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information, visit the company’s website at www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

CNS Pharmaceuticals (NASDAQ: CNSP) Announces Q1 2022 Financial, Corporate Update

May 17, 2022 10:34:55

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released its first quarter 2022 financial report along with key updates on company strategies. The report pointed to recent approvals of a potentially pivotal Berubicin study in Europe that is expected to significantly drive patient enrollment and opportunities for Berubicin to be used in additional oncology indications with significant unmet needs and also noted that CNSP was granted fast track designation for Berubicin from the FDA, which provides more frequent interactions with the agency to expedite the development and review process; the company had already received orphan drug designation for the novel anthracycline. Financial numbers for the period ended March 31, 2022, include a net loss of an estimated $2.8 million compared to approximately $3.6 million for the comparable period in 2021; R&D expenses of $1.5 million for Q1, down from approximately $2.2 million for the same period in 2021; and general and administrative expenses totaling some $1.3 million for the first quarter, remaining fairly constant when compared to $1.4 million for Q1 2021. “Since the start of 2022, we have significantly expanded our international presence with clinical approvals in Spain, France and Switzerland received for our potentially pivotal study of Berubicin for the treatment of GBM,” said CNS Pharmaceuticals CEO John Climaco said in the press release. “Once again, our team demonstrated its operational, clinical and regulatory expertise this quarter. These efforts enable us to continue building momentum with patient enrollment — the cornerstone of any successful drug development program. The unmet need in GBM is enormous and knows no geographic borders, and this critically important and state of the art trial will, most importantly, advance a much-needed potential treatment option to patients. We have been and remain laser focused on executing on all of our operational efforts and look forward to an exciting year ahead.”

To view the full press release, visit https://ibn.fm/NR6a5

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme, an aggressive and incurable form of brain cancer. Additionally, CNS Pharmaceuticals is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain, pancreatic and ovarian cancers as well as lymphomas. For more information about the company, please visit www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Mullen Automotive (NASDAQ: MULN), LGG Report on Development of Battery Cell Tech

May 17, 2022 10:34:30

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has released an update on its partnership with Linghang Guochuang Group (“LGG”). According to the update, the two companies are working together to take solid-state polymer battery cell technology into vehicle pack level development, with solid-state polymer batteries being anticipated to be available for the second generation of the Mullen FIVE EV Crossover. The two companies announced their partnership in 2019 and then progress was sidelined in 2020 because of COVID-19 outbreak. Recently, Mullen and LGG have picked up again, starting integration of the solid-state polymer cell technology into the vehicle pack level, with plans to integrate solid-state polymer batteries into the second-generation Mullen FIVE EV Crossover, giving the EV a potential range of 600 miles on a full charge with more than 300 miles of range delivered in 18 minutes when using DC fast charging. “I am pleased to announce today that Mullen Automotive and LGG are moving forward on solid-state vehicle pack level development,” said Mullen Automotive CEO and chair David Michery in the press release. “Scaling from the cell level to pack level development is a major accomplishment and one I am proud to announce is progressing with LGG as our partner.”

To view the full press release, visit https://ibn.fm/9ZGCe

About Mullen Automotive Inc.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Lottery.com (NASDAQ: LTRY) Releases Q1 Financial, Operational Results

May 17, 2022 10:33:49

Lottery.com (NASDAQ: LTRY), a leading technology company that is transforming how, where and when the lottery is played, is reporting its first quarter 2022 financial results for the period ended March 31, 2022. Highlights of the report include Q1 revenue of $21.2 million, an increase of $15.7 million from the same period the previous year, as well as gross profit totaling $18 million, up $15.5 million from first quarter 2021. The report stated that the company experience Q1 2022 net loss of $15.8 million and adjusted EBITDA of $7.7 million. In addition, the report noted an update on key initiatives for the company, including expanded B2C marketing campaigns being launched that resulted in notable increases in app downloads, new LotteryLink affiliates joining the company and the launch of Project Nexus, which is designed to improve scalability, security and ability to implement product improvements. “I’m pleased with our first quarter results and the team’s continued focus on our core business and generating strong adjusted EBITDA,” said Lottery.com cofounder and CEO Tony DiMatteo in the press release. “Once again, LotteryLink has demonstrated its ability to contribute to our top and bottom line growth and expand our user base with limited advertising spend. In our B2C business, our focus on market testing and securing permission to advertise on large digital media platforms has solidified our foundation to launch accretive user acquisition campaigns over the balance of the year. So far in the second quarter, our B2C campaigns have been positive with solid increases in app downloads versus the prior year period while achieving relatively low customer acquisition costs. LotteryLink’s promotional programs have generated new users and created interest from additional national consumer brands looking to utilize LotteryLink for their marketing campaigns. Additionally, we have launched phase 1 of Project Nexus. We believe that these positive developments, combined with our strong balance sheet, position us well for future growth.”

To view the full press release, visit https://ibn.fm/9IYym

About Lottery.com

Lottery.com is a leading technology company that is transforming how, where and when lottery is played. Its engaging mobile and online platforms enable players located in the United States and internationally to remotely purchase legally sanctioned lottery games. Fans and subscribers look to Lottery.com for compelling, real-time results on more than 800 lottery games from more than 40 countries. Commercial partners and affiliates can also utilize LotteryLink to provide Lottery.com products to their customers. Additionally through WinTogether.org, Lottery.com is fundamentally changing how nonprofit donors are incentivized to action by gamifying charitable giving. In all that it does, Lottery.com’s mission remains the same: an uncompromising passion to innovate, grow a new demographic of enthusiasts, deliver responsible and trusted solutions, and promote community and philanthropic initiatives. To learn more about the company, visit www.Lottery.com.

NOTE TO INVESTORS: The latest news and updates relating to Lottery are available in the company’s newsroom at https://ibn.fm/Lottery

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Flora Growth (NASDAQ: FLGC) Announces Appointment of Cannabis Regulatory Veteran

May 17, 2022 10:33:17

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced its appointment of regulatory veteran Holly Bell as vice president of regulatory affairs. According to the update, Bell will play a crucial role in Flora’s domestic and global expansion strategy and lead government relations in key international markets. “Holly’s unique knowledge and understanding of the United States’ regulatory framework will position us to make thoughtful, educated and bold decisions regarding strategic distribution, cultivation and sales plans,” said Luis Merchan, president and CEO of Flora Growth. “We look forward to bringing Holly’s expertise to our growing roster of industry standouts and working closely with governments worldwide to break down the barriers to the cannabis trade.”

To view the full press release, visit https://cnw.fm/fBIS7

About Flora Growth Corp.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Merck & Company Inc. (MRK) Climbs to Annual-High Share Price

May 16, 2022 11:17:21

Merck & Company Inc. (NYSE:MRK) traded at a new 12-month high today of $91.79. Approximately 3.7 million shares have changed hands today, as compared to an average 30-day volume of 12 million shares.

Merck & Company Inc. share prices have moved between a 12-month high of $91.79 and a 12-month low of $70.89 and are now trading 29% above that low price at $91.61 per share.

Based on a current price of $91.61, Merck & Company Inc. is currently 9.1% above its average consensus analyst price target of $83.27.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm’s immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to half of the firm’s sales are generated in the United States.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Watch for Continued Gains in Shares of H&R Block Inc. (HRB)

May 16, 2022 11:16:31

Shares of H&R Block Inc. (NYSE:HRB) traded today at $33.38, eclipsing its 12-month high. So far today approximately 2.4 million shares have been exchanged, as compared to an average 30-day volume of 2.4 million shares.

H&R Block Inc. provides income tax return preparation services, digital do-it-yourself tax solutions, and other services related to income tax preparation to the general public primarily in the United States, Canada, and Australia. The company mainly prepares tax returns for customers within the United States through its company-owned offices, franchise locations, and online tax software. The vast majority of H&R Block’s offices are located in the U.S. The company derives most of its total revenue from the U.S. assisted tax preparation fees. Revenue from franchise and product royalties and digital do-it-yourself tax solutions is also relatively significant.

There is potential upside of 97.6% for shares of H&R Block Inc. based on a current price of $32.43 and an average consensus analyst price target of $64.07.

H&R Block Inc. share prices have moved between a 12-month high of $33.38 and a 12-month low of $21.08 and are now trading 54% above that low price at $32.43 per share.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Knightscope’s (NASDAQ: KSCP) ASRs Facilitating Situational Crime Prevention

May 16, 2022 11:11:46

The various opportunity-reducing methods of situational crime prevention look to increase the perceived risks of committing a crime, enhance the effort required to commit crimes, reduce rewards, and eliminate excuses for crime
Knightscope’s autonomous security robots (“ASRs”), which are equipped with capabilities such as video recording and streaming capabilities, thermal anomaly detection, facial recognition, and more, help to increase the perceived risks associated with criminal activities, resulting in deterrence
Following the deployment of ASRs, Knightscope’s clients have reported considerable reductions in the number of crimes reported
Knightscope recently added another client – a New York shopping center – and visited additional towns as part of its Robots Roadshow, with recent touchdowns in Columbus and Akron, Ohio

In a 1998 paper, Marcus Felson and Ronald V. Clarke, then Professors at the Rutgers University School of Criminal Justice in New Jersey, presented the ten principles of crime opportunity theory (https://ibn.fm/uUFqw), one of which guides the operations of Knightscope (NASDAQ: KSCP), an advanced security technology company that builds fully autonomous security robots (“ASR”).

The eighth principle states that crime can be prevented by reducing opportunities. And basing their discussion of this principle on situational crime prevention, the academics noted that the opportunity-reducing methods of situational crime prevention, such as…

NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

About InvestorWire

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Aditxt Inc. (NASDAQ: ADTX) Is ‘One to Watch’

May 16, 2022 11:11:07

Aditxt is commercializing new innovations with focus on mapping and reprogramming the immune system
Aditxt is actively adding distribution channel partners for AditxtScore(TM) throughout the U.S. and globally
The company aims to expand reimbursement coverage for AditxtScore(TM) for COVID-19 from private insurance and public payers while developing and commercializing tests for other indications
Aditxt intends to advance its ADi(TM) therapeutics pipeline into clinical trials in the coming months, with initial studies targeting psoriasis, type 1 diabetes, and skin allograft transplantation
The company is led by a team of experts coming from a variety of different scientific fields and business backgrounds

Aditxt (NASDAQ: ADTX) is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. Aditxt’s immune mapping technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

As further discussed below, the company’s first commercial product is an immune mapping technology, AditxtScore(TM), which is designed to provide a personalized profile of the…

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Lexaria (NASDAQ: LEXX) Devoting Research to Making Drug Substances More Effective

May 13, 2022 13:41:06

Lexaria Bioscience Corp. (NASDAQ: LEXX) is devoting its research and product development to making drug substances more effective in the approach to treating medical conditions such as high blood pressure and, in the process, to overcoming many obstacles that may hinder their proper use by patients. “One area of Lexaria’s research has focused on pursuing U.S. Food and Drug Administration (‘FDA’) approval to begin formal, registered clinical testing of its DehydraTECH-processed cannabidiol (‘CBD’) for the treatment of hypertension under the Investigational New Drug (‘IND’) process,” a recent article reads. “Lexaria recently announced the launch of its HYPER-H21-4 randomized, double-blinded, placebo-controlled, cross-over study of DehydraTECH-CBD in relation to hypertension, with the potential for enhancing Lexaria’s ability to treat cardiovascular and other disease states beyond hypertension that are related to increased arterial stiffness. Lexaria has already completed other human studies. Last year, studies HYPER-H21-1 and HYPER-H21-2 provided evidence that DehydraTECH-CBD successfully reduced blood pressure in similarly hypertensive human volunteers, and Lexaria announced earlier this month that it had completed all data analyses of its HYPER-H21-3 study with positive safety and efficacy findings.”

To view the full article, visit https://cnw.fm/AGTTW

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

InMed Pharmaceuticals (NASDAQ: INM) Announces Q3 Fiscal 2022 Financial Results

May 13, 2022 13:40:27

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced financial results for the third quarter ended March 31, 2022. “The third quarter of fiscal 2022 saw noticeable advancements across all of our programs, including commencing sales of the rare cannabinoids CBDV and CBT as raw ingredients for the health and wellness industry,” said Eric A. Adams, InMed president and CEO. “For the remainder of fiscal 2022, we will remain focused on driving our commercial operations by expanding our product portfolio, increasing sales of our existing and new rare cannabinoids, exploring new distribution channels and optimizing our product development and supply chain strategy. We continue to grow revenues and have established a solid platform upon which to build as we commercialize additional high value products. We continue to focus on enhancing our sales and marketing efforts to support increasing demand.”

To view the full press release, visit https://ibn.fm/h3oci

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary BayMedica LLC, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is also a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com and www.BayMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Mullen Automotive (NASDAQ: MULN) Announces Q2 Preliminary Financial Results

May 13, 2022 13:39:48

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced preliminary financial results (subject to change) for its period ending March 31, 2022. Among the highlights, the company reported cash and cash equivalents amounting to $65.2 million, as well as total debt of $22.1 million continuing its downward trend. In May 2022, Mullen signed a proposal with Thurner Design for the vehicle development of the Mullen FIVE RS, a high-performance EV sport crossover vehicle featuring close to 1,100 HP, 0-60 mph in just 1.95 seconds, and 200 mph top speed. Further, Mullen FIVE reservations increased substantially and more than doubled the volume attained in the last quarter of 2021, which included the world debut of the Mullen FIVE at the Los Angeles International Auto Show in November 2021. Reservation progress continues to build, showing strong consumer interest.

“We have made significant progress during the second quarter and have demonstrated significant finance progress for moving forward,” said David Michery, CEO and chairman of Mullen Automotive. “Our balance sheet continues to improve, and our EV programs are all moving forward, including the start of the Mullen FIVE RS program.”

To view the full news release, visit https://ibn.fm/UnkVK

About Mullen Automotive Inc.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Golden Matrix Group (NASDAQ: GMGI) Leading Way to Better Player Retention, Profits

May 13, 2022 13:39:28

GMGI white labels turnkey online casino, sportsbook, and live gaming content solutions complete with a single wallet for players for both desktop and mobile applications
Y-o-Y revenue soared 355% to $8.88 million in Q1 fiscal 2022 with 500+ different casino brands and over 6 million players supporting GMGI’s 14th straight profitable quarter
Golden Matrix recently acquired R Kings Competition, a leading competitions platform that generated more than $29 million in revenue and net income above $2.4 million in the recent year

With online wagering becoming increasingly popular – and legalized in 18 U.S. states so far since PAPSA was overturned in 2018 – the race is always on to capture users. Odds are that most people have seen an advertisement offering lucrative incentives trying to lure bettors to a particular platform. In the world of B2C (business-to-consumer) gaming, there is a fine balance that needs to be struck between user acquisition expense and revenue per user, an equilibrium that most digital platforms fail to maintain.

Gaming companies don’t mind giving out $100, $200, $300 to a new user under the contention that they will get much more back in the long run. Thing is, it’s not that simple and many gaming…

NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

About InvestorWire

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Odyssey Health (ODYY) Announces Positive Results from Phase I Clinical Trial

May 12, 2022 15:03:22

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-saving medical products, has announced positive results from the first group of patients dosed with PRV-002 in its phase I clinical trial. According to the update, Odyssey’s trial is administering PRV-002, its novel drug to treat concussion, to healthy human subjects. Thus far, the drug has shown to be safe and well tolerated. “Based on our animal data and after reviewing our initial phase I trial safety reports, we are optimistic that PRV-002 will be a safe option for the treatment of concussion,” said Michael Redmond, CEO of Odyssey Health. “We look forward to completing the phase I trial and presenting our findings to the FDA. Following FDA review, we intend to initiate a phase II clinical trial in the U.S., starting with our military. We have created a military advisory board to assist with this effort.”

To view the full press release, visit https://ibn.fm/k8fpb

About Odyssey Health Inc. (formerly Odyssey Group International Inc.)

Odyssey is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey’s corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Golden Matrix (NASDAQ: GMGI) Delivers Exactly What iGaming Operators Need

May 12, 2022 12:34:00

Every gambler is on the lookout for a lock, but as every gambler knows, the only sure way to double your money is to fold it over and tuck it in your pocket. Humanity’s penchant for gambling traces back to state-run lottos in 200 BC China to the first U.S. online lotto in 1994 and now proliferates across the globe on PCs and mobile devices. Transacted through internet platforms, online gaming (or internet gambling) offers inventive games of chance as well as virtual poker and sports betting. The online gaming market is booming, eclipsing $70 billion last year, and all manner of casinos and upstart platforms are scrambling for a piece of the action. As lucrative as this all sounds there’s an Achilles heel for these platforms: customer acquisition cost vs. customer lifetime value. In the United States, the customer acquisition cost for an online casino player is more than $500, and some estimate player value at $300 or less. The math simply doesn’t work, and some online casino operators have come to realize that traditional advertising for sports betting and iGaming products presents an irrational cost of customer acquisition. With the online gaming market expected to explode to more than $130 billion in the next five years, there may be a smarter way to cash in on the action. Much like the merchants that made millions during the gold boom while prospectors panned for dreams, providing B2B services such as online gaming platforms, systems and gaming content has proved to be a winning business model. Coming off its 14th consecutive quarter of profitability, Golden Matrix Group Inc. (NASDAQ: GMGI) (Profile) continues to carve out enviable market share by delivering state-of-the-art configurable and scalable white-label B2B gaming platforms for its customers across the globe. Golden Matrix’s gaming IP includes sophisticated tools for marketing, acquisition, retention and monetization of users — exactly what iGaming operators need. With more than 580 unique casino operations, 30-plus partnerships, 6 million-plus end users and 3,161 original games, Golden Matrix has established itself as one of the world’s leading providers of turnkey and white-label gaming platforms, Esports technology and gaming content, and the company has even bigger plans for market dominion. All the major casino operators, including Caesars Entertainment Inc. (NASDAQ: CZR), Penn National Gaming Inc. (NASDAQ: PENN), MGM Resorts International (NYSE: MGM) and Las Vegas Sands Corp. (NYSE: LVS) are trying to entice users to download their apps as they fight for a piece of the online action and struggle with customer acquisition costs.

To hear the NetworkNewsAudio version, visit https://nnw.fm/IdUz0

To view the full editorial, visit https://nnw.fm/H94XC

About Golden Matrix Group Inc.

Golden Matrix Group, based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds configurable and scalable white-label B2B gaming platforms for its international customers, located primarily in the Asia-Pacific region. The company’s gaming IP includes tools for marketing, acquisition, retention and monetization of users. GMGI’s platform can be accessed through both desktop and mobile applications. As a result of its 80 percent controlling ownership interest in UK-based RKings Competitions Ltd., Golden Matrix also generates revenues from RKings’ scalable B2C tournament platform. For more information about the company, visit www.GoldenMatrix.com

NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://nnw.fm/GMGI

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit www.NetworkNewsAudio.com

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

NetworkNewsWire is part of the InvestorBrandNetwork.

Cepton Technologies (NASDAQ: CPTN) Releases Financial Report for Q1 2022

May 12, 2022 12:33:39

Cepton Technologies (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance Micro Motion Technology(RM) (“MMT”) lidar solutions, is reporting its financial numbers for the first quarter 2022, the period ended March 31, 2022; the report also includes corporate updates. Highlights of the report include an increase in revenue, with Q1 2022 revenue reaching $1.5 million, up 239% compared to the previous year, and net income of $41.2 million, compared to a GAAP net loss of $8.4 million last year in the same period. In addition, first quarter 2022 non-GAAP net loss was $12.2 million compared to non-GAAP net loss of $8.1 million in the prior year period. In addition, regarding the OEM Series, the company started shipping D-sample in support of the GM Ultra Cruise program for an anticipated start of production in 2023 and began transfer of the manufacturing processes, equipment and software to Koito in preparation for series production. The company, which continues to engage with global top-10 automotive OEMs for production vehicle programs, has also completed proof-of-concept validation for multiple projects. Cepton has scheduled a conference call to discuss this information; the call will begin at 5 p.m. ET today and can be listened to by calling 844-826-3035; the call can be viewed as a webcast as well. “Following our public listing in February this year, Cepton is well equipped to execute on its 2022 milestones and deliver long-term value to our shareholders,” said Cepton cofounder and CEO Jun Pei in the press release. “We continue to make progress on series production execution milestones, with D-sample units being shipped to multiple manufacturing sites across the United States, bringing us one step closer to seeing Cepton’s industry-leading lidar products in everyday vehicles. On the horizon, we have completed key design milestones on Nova, our near-range lidar solution and our second ASIC, that will enable further performance enhancement and cost reduction benefits.”

To view the webcast, visit https://ibn.fm/ktIqe

To view the full press release, visit https://ibn.fm/XJZOo

About Cepton Technologies Inc.

Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented Micro Motion Technology (“MMT”), Cepton aims to take lidar mainstream and achieve its vision of safe and autonomous transportation for everyone. Cepton has been awarded the largest-known ADAS lidar series production award in the industry to date, based on the number of vehicle models awarded, to support General Motors’ Ultra Cruise program. Cepton is also engaged with all other top-10 global OEMs. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high-performance, high-quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to the OEM and Tier 1-studded metro Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information about the company, visit www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Flora Growth (NASDAQ: FLGC) Expands Footprint to Establish Presence in the UK and EU

May 12, 2022 12:33:19

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced expansion of its operational footprint in Europe and the United Kingdom, furthering its international growth strategy. According to the update, the London-based offices will serve as the regional headquarters for Flora’s sales force and management of its distribution centers in the U.K. and Netherlands. Flora additionally bolsters its strategic positioning in the region by partnering with Hoshi to distribute the company’s broader product portfolio to 11 countries, including Germany, Portugal, the U.K., Italy, Poland, the Czech Republic, Denmark, the Netherlands, Switzerland, Malta, and Macedonia. “Establishing our roots in the U.K. and EU will not only afford us opportunities to increase our distribution and grow market share, but it will generate actionable market insights for our team to continue to innovate and deliver the most compelling experiences we can,” said Luis Merchan, president and CEO of Flora. “The latest global expansion highlights our commitment to driving exponential growth and scale.”

To view the full press release, visit https://cnw.fm/K5Jvt

About Flora Growth Corp.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Flora Growth (NASDAQ: FLGC) Announces Launch of Vessel in Canada, OCS Partnership

May 11, 2022 13:44:56

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that its Vessel brand, a leader in premium cannabis accessories, secured meaningful penetration in Canada via an approved listing on the Ontario Cannabis Store (“OCS”). In addition, Vessel has launched its Canadian direct-to-consumer online store, www.VesselBrand.ca, to service customers directly across the country. “We’re elated about our partnership with the OCS and are looking forward to bringing the full Vessel experience to our loyal customers across Canada,” said Flora’s Chief Strategy Officer James Choe. “Our internal estimates show the Canadian cannabis market will be around CAD 5.9 billion this year, with the ancillary category making up about $350 – $475 million. That market potential, coupled with our expectations around meaningful retail door penetration across the country, signals promising growth in this market.”

To view the full press release, visit https://cnw.fm/OyiyS

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands to deliver the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. Visit www.FloraGrowth.com or follow @floragrowthcorp on social media for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

How to Win with Online Gambling

May 11, 2022 13:44:29

NetworkNewsWire Editorial Coverage: Luck is a huge aspect of gambling, but luck has a way of favoring the intelligent and showing its back to the foolish. Good online gamblers look for opportunities to improve their odds, then press when probabilities are in their favor. Luck is a fickle mistress and good gamblers know that luck is what happens when preparation meets opportunity. The seduction of gambling dates as early as 200 BC and now flourishes on PCs and mobile devices around the world. Eclipsing $70 billion last year, major casinos and new gaming platforms are fighting for a piece of the action. The market is booming, but there’s a serious drawback for these platforms. Customer acquisition cost for an online casino in the United States is more than $500, and some estimates peg player value at $300 or less. That’s not a winning formula, and many online casino operators now realize that traditional advertising for sports betting and iGaming products presents an irrational cost of customer acquisition. With the online gaming market expected to balloon to more than $130 billion in the next five years, there may be a smarter way to cash in on the action. Providing B2B services such as online gaming platforms, systems, and gaming content has proved to be a winning business model. Coming off its 14th consecutive quarter of profitability, Golden Matrix Group Inc. (NASDAQ: GMGI) is capturing enviable market share delivering state-of-the-art configurable and scalable white label B2B gaming platforms for its customers across the globe. Golden Matrix’s gaming IP includes sophisticated tools for marketing, acquisition, retention, and monetization of users, exactly what platform operators need to achieve profitability. Golden Matrix has established itself as one of the world’s leading providers of turnkey and white label gaming platforms, gaming content, and Esports technology. Others in the sector, such as DraftKings Inc. (NASDAQ: DKNG), International Game Technology (NYSE: IGT), Bragg Gaming Group Inc. (NASDAQ: BRAG) and GAN Limited (NASDAQ: GAN), are also working to expand into new markets and increase…

Cybin (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright Conference

May 11, 2022 13:44:01

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its CEO Doug Drysdale will participate in a fireside chat at the H.C. Wainwright Global Investment Hybrid Conference. The event is taking place May 23-26, 2022, at the Fontainebleau Miami Beach. Drysdale’s fireside chat will be webcast live at 12:30 p.m. ET on Wednesday, May 25. Interested parties should visit https://ibn.fm/0nlvQ to register and access the live webcast. An archived version of the webcast will also be available on the company’s investor relations website.

To view the full press release, visit https://ibn.fm/34DNj

About Cybin Inc.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience’s (NASDAQ: LEXX) DehydraTECH(TM) Influencing the Pharma Industry

May 11, 2022 13:43:36

Lexaria began its human clinical study on oral nicotine alternatives, evaluating the effectiveness of its DehydraTECH-nicotine pouch performance
Earlier in the year, the company also announced the commencement of its HYPER-H21-4 human clinical study on the effectiveness of DehydraTECH-processed CBD for hypertension treatment
Lexaria has also made some significant progress in the use of its technology for the enhanced delivery of antiviral drugs
It hopes that before the end of 2022, it will have built sufficient data to effect meaningful industry progress and sustainable increases in valuation

Lexaria Bioscience (NASDAQ: LEXX), since its inception, has been pushing the boundaries of drug delivery. Through its patented technology, DehydraTECH(TM), the company has achieved more efficient delivery of active pharmaceutical ingredients into the bloodstream while also increasing their bioavailability.

Its technology has seen application in pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter capsules, pills, tablets, and oral suspensions. Lexaria has explored its usage in the…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]

CBDWire is part of the InvestorBrandNetwork.

Investor Event Puts Spotlight on Brain Cancer Drug Trial by CNS Pharmaceuticals (NASDAQ: CNSP)

May 11, 2022 13:43:04

CNS Pharmaceuticals is developing a proprietary drug candidate that has the potential to deliver a novel solution for unmet medical needs in treating an incurable brain cancer
CNS’s drug candidate is called Berubicin, a powerful anthracycline that appears to be the first such chemotherapy agent able to successfully cross the blood-brain barrier
Berubicin dosing has begun in a potentially pivotal global trial that is recruiting glioblastoma multiforme (“GBM”) brain cancer patients
The FDA has granted CNS fast-track authorization in regard to Berubicin’s development, and European countries’ drug regulatory bodies are also granting authorization to advance the trial process there
An April 14 Virtual Investor Spotlight Event provided investors with information on CNS’s efforts, and the Zoom webcast will remain viewable through July for interested parties

Investors interested in potentially getting on board with a biopharmaceutical company working to develop novel brain cancer solutions can learn about the unmet need for treating deadly glioblastoma (“GBM”) and the work CNS Pharmaceuticals (NASDAQ: CNSP) is putting into granting GBM patients new hope by reviewing a recent Virtual Investor Spotlight Event that will be viewable for the next few weeks.

The spotlight event (event can be accessed at https://ibn.fm/QhlSJ, presented by corporate and private client services advisors at JTC IR showcases CNS’s novel anthracycline Berubicin, which appears to be…

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

GreenBox (NASDAQ: GBOX) to Report Q1 2022 Results on May 16

May 9, 2022 12:08:27

GreenBox (NASDAQ: GBOX), an emerging and rapidly growing fintech company, has announced its intention to release its first quarter 2022 financial results after market close on Monday, May 16, 2022. As part of that release strategy, company executives will host a conference call/webcast to discuss the results and provide a corporate update on that same day; the call will include a Q&A session. The call is slated to start at 4:30 p.m. ET, and those who are interested can dial 1-844-825-9789 in the United States or 1-412-317-5180 internationally, using the conference ID 10166964; callers are encouraged to dial in at least 10 minutes before the start of the event to ensure participation. A replay of the call will be available through Aug. 16, 2022. Those interested in listening to the replay can dial 1-844-512-2921 in the United States or 1-412-317-6671 internationally and enter replay pin number 10166964. A webcast replay will be available on the company’s website.

To view the webcast, visit https://ccw.fm/jaL0o

To view the full press release, visit https://ccw.fm/lIrVL

About GreenBox POS

GreenBox is an emerging financial technology company leveraging proprietary blockchain security and token technology to build customized payment solutions. The company’s applications enable an end-to-end suite of turnkey financial products with fraud detection technology, improving the efficiency of handling large-scale commercial processing volumes for its merchant clients. For more information about the company, please visit www.GreenBoxPOS.com.

NOTE TO INVESTORS: The latest news and updates relating to GBOX are available in the company’s newsroom at https://ccw.fm/GBOX

About CryptoCurrencyWire (“CCW”)

To receive instant SMS alerts, text “CRYPTO” to 844-397-5787 (U.S. Mobile Phones Only)

CryptoCurrency News Wire is where News, content and information converge via Crypto.

For more information, please visit https://www.CryptoCurrencyWire.com

Please see full terms of use and disclaimers on the CryptoCurrencyWire (CCW) website applicable to all content provided by CCW, wherever published or re-published: http://CCW.fm/Disclaimer

CryptoCurrencyWire (CCW)
New York, New York
www.CryptoCurrencyWire.com
212.994.9818 Office
[email protected]

CryptoCurrencyWire is part of the InvestorBrandNetwork

SRAX (NASDAQ: SRAX) Building on Growth Momentum to Bring Cutting-Edge Solutions

May 9, 2022 12:07:42

SRAX (NASDAQ: SRAX) is a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform. The company appears poised to build upon its growth momentum to expand beyond the investor relations space to include integrated cross-organizational solutions that can be deployed across multiple departments. A recent article reads: “The company continues to go from strength to strength and has grand plans for 2022. In a recent episode of a Sequire Spotlight series called Sequire Spotlight Presents SRAX (SRAX): The Savvy Solution to Investor Relations, SRAX’s CEO Christopher Miglino revealed that the product roadmap involves expanding the portfolio to include innovative technology that can be deployed across the whole enterprise. The company appears poised to take its holistic approach beyond the investor relations space to include solutions that are more integrated into the organization, from finance to marketing. As a technology-centric company committed to building new products fast, SRAX has been working on delivering these new cutting-edge solutions to the marketplace in the months to come.”

To view the full article, visit https://ibn.fm/u7wPd

About SRAX Inc.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Cepton (NASDAQ: CPTN) Bridging Divide Between Science, Automotive Industry

May 9, 2022 12:07:18

Cepton (NASDAQ: CPTN) recently became a sponsor and an exclusive LiDAR provider for ten universities in North America gathered in a four-year STEM education program called The AutoDrive Challenge(TM) II. The program is designed to advance STEM education and contribute to groundbreaking work within the autonomous driving space. “As a leading innovator in the LiDAR space, Cepton has always been committed to becoming the bridge between cutting-edge science and the automotive industry. Autonomous driving and its great enabler – LiDAR technology – are ready to take over the mobility space as the innovative technology makes strides in terms of decreasing costs and improving commercial potential. Cepton appears determined to be a visible part of that landscape,” a recent article reads. Dr. Jun Pei, CEO of Cepton, said, “LiDAR is going mainstream with it being deployed in advanced driver assistance systems (‘ADAS’) in everyday consumer vehicles to be available in the next few years. This sensor technology is not only capable of improving vehicle safety but also critical in enabling higher levels of autonomy. We are dedicated to helping proliferate the benefits of LiDAR technology by focusing on its mass-market scalability with our proprietary Micro Motion Technology (MMT(R))….”

To view the full article, visit https://ibn.fm/pBmDx

About Cepton Inc.

Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented Micro Motion Technology (“MMT(R)”), Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability, while enabling scalable and intelligent 3D perception solutions across industries. Cepton has been awarded the largest known ADAS lidar series production award in the industry to date, based on the number of vehicle models awarded, to support General Motors’ Ultra Cruise program. Cepton is also engaged with all other Top 10 global OEMs. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to the OEM and Tier 1-studded Metro Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information, visit the company’s website at www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Online Gaming — A Sure Bet

May 9, 2022 12:06:37

NetworkNewsWire Editorial Coverage: Every gambler is on the lookout for a lock, but as every gambler knows, the only sure way to double your money is to fold it over and tuck it in your pocket. Humanity’s penchant for gambling traces back to state-run lottos in 200 BC China to the first U.S. online lotto in 1994 and now proliferates across the globe on PCs and mobile devices. Transacted through internet platforms, online gaming (or internet gambling) offers inventive games of chance as well as virtual poker and sports betting. The online gaming market is booming, eclipsing $70 billion last year, and all manner of casinos and upstart platforms are scrambling for a piece of the action. As lucrative as this all sounds there’s an Achilles heel for these platforms: customer acquisition cost vs. customer lifetime value. In the United States, the customer acquisition cost for an online casino player is more than $500, and some estimate player value at $300 or less. The math simply doesn’t work, and some online casino operators have come to realize that traditional advertising for sports betting and iGaming products presents an irrational cost of customer acquisition. With the online gaming market expected to explode to more than $130 billion in the next five years, there may be a smarter way to cash in on the action. Much like the merchants that made millions during the gold boom while prospectors panned for dreams, providing B2B services such as online gaming platforms, systems and gaming content has proved to be a winning business model. Coming off its 14th consecutive quarter of profitability, Golden Matrix Group Inc. (NASDAQ: GMGI) (Profile) continues to carve out enviable market share by delivering state-of-the-art configurable and scalable white-label B2B gaming platforms for its customers across the globe. Golden Matrix’s gaming IP includes sophisticated tools for marketing, acquisition, retention and monetization of users — exactly what iGaming operators need. With more than 580 unique casino operations, 30-plus partnerships, 6 million-plus end users and 3,161 original games, Golden Matrix has established itself as one of the world’s leading providers of turnkey and white-label gaming platforms, Esports technology and gaming content, and the company has even bigger plans for market dominion. All the major casino operators, including Caesars Entertainment Inc. (NASDAQ: CZR), Penn National Gaming Inc. (NASDAQ: PENN), MGM Resorts International (NYSE: MGM) and Las Vegas Sands Corp. (NYSE: LVS) are trying to entice users to download their apps as they fight for a piece of the online…

Flora Growth (NASDAQ: FLGC) Schedules Webcast to Discuss 2021 Financial Results